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Resumo
O cancro de pro´stata e´ o segundo tipo de cancro com maior prevaleˆncia nos homens, em todo o
mundo. A detec¸a˜o inicial desta doenc¸a ocorre, geralmente, durante exames e consultas de rotina,
quando n´ıveis aumentados do antige´nio prosta´tico espec´ıfico e/ou um exame retal anormal sa˜o
descobertos. Contudo, apenas a avaliac¸a˜o histopatolo´gica, inicialmente baseada em amostras
extra´ıdas atrave´s de uma bio´psia, e´ capaz de fornecer um diagno´stico definitivo, permitindo na˜o
so´ orientar o tratamento do doente, assim como o processo de tomada de decisa˜o associado.
Apo´s esta avaliac¸a˜o inicial, se o doente for diagnosticado com cancro da pro´stata localizado, ou
seja, um tumor confinado a` pro´stata, o tratamento mais adotado e´ a prostatectomia radical.
Este u´ltimo e´ o tratamento padra˜o utilizado quando se pretende uma terapia com curativa. A
vantagem da te´cnica de prostatectomia radical e´ que, toda a pro´stata, onde o tumor se encontra
confinado, e´ removida cirurgicamente, auxiliando na reduc¸a˜o do risco de meta´stases.
A posterior ana´lise da pec¸a prosta´tica permite ao patologista avaliar diversas caracter´ısticas
tumorais, determinantes no progno´stico do doente. Para este fim, o microsco´pio tem sido a prin-
cipal ferramenta utilizada, uma vez que proporciona imagens ao vivo com uma o´tima resoluc¸a˜o.
No entanto, desde a introduc¸a˜o do primeiro sistema automatizado de digitalizac¸a˜o de laˆminas em
imagens de alta resoluc¸a˜o, o interesse da comunidade de anatomia patolo´gica em explorar este
tipo de me´todos para diferentes aplicac¸o˜es tem crescido exponencialmente. O potencial desta
nova a´rea na˜o e´, todavia, a simples transfereˆncia de uma imagem da laˆmina de vidro para um
monitor, nem ta˜o pouco a flexibilidade de distribuic¸a˜o e modificac¸a˜o da pro´pria imagem digital,
mas sim, a possibilidade de aprimorar a avaliac¸a˜o do patologista com informac¸o˜es e inteligeˆncia
que na˜o podem ser detetados pela ana´lise humana.
Por conseguinte, a implementac¸a˜o de algoritmos de aprendizagem automa´tica capazes de
executar tarefas como detec¸a˜o, classificac¸a˜o e segmentac¸a˜o de imagens digitais histopatolo´gicas e´,
finalmente, poss´ıvel. Estes me´todos de ana´lise automatizada permitem explorar todo o panorama
morfolo´gico do tumor e dos seus elementos mais invasivos presentes, capturando, por exemplo,
a orientac¸a˜o nuclear, a textura, a forma e a arquitetura. A complexidade e densidade inerente a
este tipo de imagens, oferecem uma abundaˆncia de informac¸a˜o, ideal para estimular e promover
o desenvolvimento de algoritmos baseados em deep learning. No que diz respeito ao cancro da
pro´stata, os algoritmos desenvolvidos visam apoiar as avaliac¸o˜es efetuados pelos patologistas,
nomeadamente, estadiamento e classificac¸a˜o, sendo, portanto, focados no sistema de classificac¸a˜o
utilizada para a pro´stata - o Gleason score. Contudo, problema´ticas alternativas podem tambe´m
beneficiar da aplicac¸a˜o destas te´cnicas, nomeadamente me´todos capazes de distinguir imagens
que apenas conteˆm tecido benigno de imagens em que tumor esteja presente. Por outro lado,
modelos capazes de prever a recidiva bioqu´ımica de cancro da pro´stata permitiriam aos me´dicos
modificar estrate´gias de tratamento e po´s-tratamento, a fim de equilibrar benef´ıcios e efeitos
adversos de um terapia espec´ıfica. A previsa˜o de recidiva permite, tambe´m, que os pacientes
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escolham com responsabilidade os diferentes tratamentos e estrate´gias que lhes sa˜o propostos
pelos me´dicos, possibilitando, em u´ltima ana´lise, uma maior sua satisfac¸a˜o apo´s o tratamento.
Desta forma, com o objetivo de explorar os referidos problemas, a presente dissertac¸a˜o apre-
senta procedimentos de recolha, processamento e anotac¸a˜o de dados, que permitiram a criac¸a˜o
de uma base digital de dados histolo´gicos anotados da pro´stata. Com base nestes dados dois
modelos distintos de deep learning, especificamente Convolutional Neural Networks foram desen-
volvidos. O modelo I propo˜e a identificac¸a˜o de cancro da pro´stata e diferenciac¸a˜o entre tumor
e tecido benigno. O modelo II pretende prever a condic¸a˜o de recidiva bioqu´ımica do cancro de
pro´stata, para um per´ıodo de tempo posterior a` cirurgia em dois anos.
Relativamente ao desenvolvimento da base de dados, 200 casos de cancro da pro´stata, trata-
dos atrave´s de prostatectomia radical, foram selecionados. As laˆminas correspondentes a` lesa˜o
ı´ndice, ou seja, a` lesa˜o principal, foram identificadas e, apenas estas foram inclu´ıdas na amostra
final. A adoc¸a˜o desta abordagem deveu-se ao facto de que cada pec¸a origina entre 15-45 laˆminas,
sendo que a maioria na˜o conte´m tumor. Por outro lado, dado o per´ıodo de tempo para a real-
izac¸a˜o de todo este projeto, seria invia´vel a utilizac¸a˜o de todas as laˆminas. Assim, as laˆminas
selecionadas foram digitalizadas e processadas. Uma te´cnica de normalizac¸a˜o de contraste foi
aplicada, de forma a uniformizar as cores das diferentes imagens digitais, evitando uma elevada
variabilidade de contraste e cor que adve´m da utilizac¸a˜o de diferentes protocolos de cor, bem
como da pro´pria digitalizac¸a˜o da laˆmina. As imagens histolo´gicas digitalizadas e normalizadas
foram posteriormente divididas em imagens mais pequenas, isto e´, subimagens, uma vez que
desta forma existe uma otimizac¸a˜o da extrac¸a˜o de caracter´ısticas por parte dos algoritmos. Es-
tas subimagens foram individualmente visualizadas e anotadas, originando um total de cerca de
160,000 subimagens, correspondentes aos 200 casos diferentes selecionados.
Para o desenvolvimento do modelo de classificac¸a˜o do cancro de pro´stata, a arquitetura
Inception v3 foi implementada e treinada utilizando as subimagens da base de dados. Este
modelo foi capaz de identificar treˆs classes distintas: negativa (tecido benigno), positiva (tecido
maligno) e neoplasia intraepitelial da pro´stata, esta u´ltima, embora com menor precisa˜o dada a
quantidade reduzida de exemplos pertencentes a esta classe. Um valor de 93 % de precisa˜o foi
obtido, o que corresponde a valores equiparados ao estado da arte para este tipo de te´cnicas.
Este valor, contudo, demonstra ainda potencial para otimizac¸a˜o e melhoria, uma vez que as
diferentes classes dos dados utilizados seguiam uma distribuic¸a˜o na˜o equilibrada. A inclusa˜o
de mais casos cl´ınicos e a aplicac¸a˜o de te´cnicas de aumento de dados, podem ser facilmente
realizadas, o que culminara´ num modelo com ainda melhor precisa˜o de classificac¸a˜o.
Relativamente ao modelo referente a` previsa˜o de recidiva bioqu´ımica, a mesma arquitetura foi
utilizada, mas neste caso, treinada apenas com base nas subimagens positivas, isto e´, as subim-
agens contendo tecido maligno da pro´stata. Os resultados obtidos revelaram que este modelo
na˜o tem a capacidade de extrair informac¸a˜o relevante correlacionada com o objetivo do estudo,
e portanto, na˜o consegue distinguir com sucesso casos na˜o recorrentes de casos recorrentes, pro-
duzindo apenas uma precisa˜o de 60 %. Contudo, apesar do referido modelo falhar na execuc¸a˜o
do objetivo estipulado, e´ fundamental notar que a tarefa de predic¸a˜o de recidiva bioqu´ımica e´
de complexidade elevada, na˜o sendo poss´ıvel aos patologistas, atrave´s da observac¸a˜o das ima-
gens histolo´gicas, retirar nenhuma conclusa˜o que diretamente se correlacione com esta condic¸a˜o.
Diferentes abordagens, como por exemplo, o aumento da quantidade de dados utilizados, a
introduc¸a˜o no modelo de caracter´ısticas cl´ınicas relevantes no progno´stico da doenc¸a podera˜o
apresentar melhorias substanciais, no que diz respeito a` capacidade preditiva deste modelo.
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Concluindo, a capacidade de algoritmos de deep learning para extrair informac¸a˜o relevante
de imagens digitais da histopatologia da pro´stata foi demonstrada atrave´s do presente estudo.
O desenvolvimento e o criac¸a˜o de uma base de dados anotados, fornece a base fundamental
para o desenvolvimento de modelos adicionais, onde diversas questo˜es podem ser exploradas. O
desenvolvimento de uma interface que permita implementar o modelo de detec¸a˜o de cancro da
pro´stata desenvolvido e´ tambe´m uma possibilidade, uma vez que fornece eficieˆncia e consisteˆncia,
beneficiando a pra´tica da patologia clinica.
Palavras-Chave: Cancro da Pro´stata; Recidiva Bioqu´ımica; Patologia Digital; Deep Learn-
ing.
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Abstract
Prostate cancer is the second most prevalent cancer in men, worldwide. Histopathologi-
cal assessment plays an indispensable role in understanding the disease mechanisms, providing
definitive diagnosis to guide patient treatment and management decisions. The microscope has
been the primary tool to this end, producing images at increased resolution. However, with the
development of the first automated high resolution whole-slide imaging system, which allows the
digitisation of glass slides, interest in using this system for different applications in pathology
practice has steadily grown, giving rise to the digital pathology field. The promise of digital
pathology is not, however, the simple transfer of an image from a glass slide to a monitor, not
even the flexibility of distribution and modification of the image, but instead the potential to
enhance the pathologist’s assessment with information and artificial intelligence that cannot be
perceived by human examination.
With the advent of digital pathology and the recent expert-level accuracy achieved by ma-
chine learning based algorithms in medical image detection, classification and segmentation,
new possibilities to develop automated image analysis methods arise. As far as prostate can-
cer is concerned, these models have been aimed at supporting pathologist’s image descriptions
such as staging and grading, being hence, focused on the Gleason grading system. In order to
explore alternative problems, the present dissertation presents data collection, processing and
annotation procedures, that allowed the creation of an annotated digital histology database of
prostate resection cases. These data was used to develop deep learning models not only to clas-
sify prostate cancer, but also to predict prostate cancer biochemical recurrence. Inception v3
architecture was implemented and trained from scratch for the proposed assignments.
The prostate cancer classification model yielded an accuracy of 93%, being able to iden-
tify three distinct classes: negative (benign tissue), positive (malignant tissue) and high-grade
prostate intraepithelium neoplasia, the latter, although, with lower precision, given to unbal-
anced class distributions. The prostate cancer biochemical prediction model was not able to
successfully distinguish between non-recurrent and recurrent cases, yielding an accuracy of 60%.
This value was accomplished, nevertheless, due to the fact that the model was classifying all en-
tries as negative, and therefore, the value of accuracy corresponds to the percentage of negative
cases present in the dataset.
Although not all models here developed achieved good results, the capacity of deep learning
algorithms to harvest relevant features from prostate histopathology digital images has been
demonstrated. The development and establishment of an annotated database provides the fun-
damental basis to further develop additional models, and mainly to improve the biochemical
recurrence prediction model by applying more sophisticated methods, given the complexity of
this problem.
Keywords: Prostate Cancer; Biochemical Recurrence; Digital Pathology; Deep Learning.
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1 INTRODUCTION
In this dissertation an approach to classification of prostate cancer and prediction of relapse
is presented. The first chapter not only offers a brief contextualisation of why prostate cancer
is a health issue, but also presents the goals of the project. Finally, the dissertation outline is
also also described.
1.1 Context and Motivation
Men who are diagnosed with prostate cancer, and the physicians who care for them are
faced with a wealth of information about this disease, including a variety of treatment options.
While some cancers lay dormant for many years, others progress rapidly, being therefore, risk
assessment a critical step in disease management, determining whether the cancer can simply be
monitored, or a radical intervention by prostatectomy is needed. Among the involved procedures,
the most important one is the examination of the biopsy and/or surgical tissue specimen by a
pathologist. The image analysis of these prostate histopathological samples is used to provide
the final detailed diagnosis and prognosis.
Current histopathology practice has several constraints, as it is highly time-consuming and
it is often prone to inconsistencies and low agreement between pathologists. The staging and
grading of prostate cancer is getting increasingly complex due to cancer incidence and patient-
specific treatment options. The detailed analysis of a single case could require several slides with
multiple stainings. Moreover, quantitative parameters are increasingly required (such as mitoses
counting), increasing the pressure on pathologists to handle large volumes of cases, while still
providing large amounts of information in the pathology reports. In this sense, the interest in
digital pathology has continuously grown.
A high resolution automated system of whole slide imaging has been a strong advance for
pathology, overcoming limitations, such as poor image quality and image navigation. It com-
plements optical microscopies, also allowing for the application of visualisation software. This
evolution can lead to virtual storage of images of pathological anatomy, and the associated es-
tablishment of global databases of histopathology images, which could be used both for clinical
and educational purposes. On the other hand, it provides the opportunity to share clinical cases
among health professionals, a key to clinical efficiency, given that the temporal window in which
the diagnosis takes place is crucial for the hope of survival of many patients.
Nevertheless, the advantages of digital pathology are not yet sufficiently explored. There is a
need to develop tools for automated tissue images processing and automated algorithm analysis
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which can positively aid pathologists in decision making and improve the diagnosis/prognosis
output. Recently, deep convolutional neural networks have revolutionised many medical image
analysis domains, one of them being histopathology image grading and classification. Further
exploration of deep learning approaches to histopathology tasks will certainly reveal its tremen-
dous potential. Therefore, in this dissertation an approach to classification of prostate cancer
and prediction of relapse is presented.
1.2 Objectives
The overall aim of the present work was to evaluate the power of machine learning based
algorithms by developing and evaluating new classification and prognostic models based on
histological digital images of the prostate. The secondary goals included:
(i) Comprehension of the main issues in classification and prediction tasks of pathology slides.
(ii) Analysis of the current literature in order to identify the state of the art workflow proce-
dures and possible optimisation strategies for the problem.
(iii) Set up a database of histopathology digital images, as well as, respective annotations.
(iv) Implementation of the identified solutions to the developed database.
(v) Evaluation of the performance of the implemented algorithms and the respective clinical
correlation.
1.3 Outline
In order to achieve the desired project goals the dissertation is divided into 8 Chapters. In
each chapter, information considered relevant for the understanding of prostate cancer biochem-
ical recurrence prediction problem and for the achievement of the proposed goals was presented.
The current chapter introduces the context, motivation and general organisation of this written
work.
In order to discuss the prostate cancer biochemical recurrence problem, a literature review
is presented in Chapter 2. A comprehensive explanation of the relevant aspects surrounding
not only the prostate gland, its anatomy and normal histology, but also prostate cancer and its
diagnosis and prognosis is provided in Section 2.1. The role of digital pathology and its contri-
bution to the current state of the art diagnosis and prognosis tools, is addressed in Section 2.2.
In Section 2.3, the fundamental concepts regarding deep learning, neural networks and convo-
lutional neural networks, a specific type of neural networks, is provided. Chapter 3 presents
a description of how the addressed problem is approached and which materials and methods
are used to solve it. The results obtained from the developed work are detailed in Chapter 4,
whereas in Chapter 5 the respective results discussion is given. Finally, Chapter 6 reports a
brief overview of the main findings, the overall conclusions of the dissertation, as well as future
perspectives.
2
2 LITERATURE REVIEW
This dissertation focus on different topics, namely prostate cancer, anatomic pathology and
deep learning. Therefore, the presented chapter is devoted to present all of these concepts.
2.1 Prostate Gland
This section is dedicated to detail important aspects related to the prostate. An introduction
of the normal prostate anatomy and histology will be presented and the remaining content is
focused on prostate cancer: diagnosis strategies, histopathology, treatment options and relapse.
2.1.1 Prostate Anatomy and Histology
The human prostate is a walnut-sized organ of the male reproductive system, located in
the pelvic cavity. Its function is to secrete fluid, which is one of the components of the semen.
Anatomically, the prostate surrounds the urethra and its base is located at the bladder neck,
while its apex at the urogenital diaphragm [1] (Figure 2.1). The urethra courses through the
gland (known here as the prostatic urethra) and exits inferiorly at the apex. The Denonvilliers’
fascia, a thin, filmy layer of connective tissue, separates the prostate and seminal vesicles from
the rectum posteriorly [2].
Figure 2.1: Sagittal section of the male pelvis. Adapted from [3].
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In the twentieth century, the prostate gland was described, by several investigators, as being
a lobular organ [4–6]. However, subsequent exploration of its anatomy established the current
and most widely accepted concept of various prostate zones, rather than prostate lobes [7]. A
three-zone model defines the transitional zone, central zone and peripheral zone (Figure 2.2).
Additionally, there is the anterior fibromuscular stroma.
The transition zone consists of two equal portions of glandular tissue lateral to the urethra
in the midgland. The central zone is a cone-shaped area of the adult gland, with the apex of
the cone at the confluence of the ejaculatory ducts and the prostatic urethra. The peripheral
zone comprises the prostatic glandular tissue at the apex, as well as, all the tissue located
posteriorly near the capsule. This zone is commonly more prone to be affected by carcinoma,
chronic prostatitis, and postinflammatory atrophy when compared to other zones. The anterior
fibromuscular stroma forms the convexity of the anterior external surface, extending from the
bladder neck to the apex of the prostate [8, 9].
Figure 2.2: Zonal anatomy of the normal prostate as described by McNeal [7–9]. The transition zone comprises
only 5%–10% of the glandular tissue in the young male. The central zone forms part of the base of the prostate
and it is traversed by the ejaculatory ducts. The prostate is constituted by the peripheral zone, particularly distal
to the verumontanum. Adapted from [3].
The prostatic capsule is composed of fibromuscular stroma which disappears towards the
apex of the gland. Although the term “capsule” is commonly used and found in the literature,
there is no consensus about the presence of a true capsule [10, 11].
The seminal vesicles are superiorly and posteriorly located to the base of the prostate. They
undergo confluence with the vas deferens on each side to form the ejaculatory duct complex,
which consists of two ejaculatory ducts along with a second loose stroma rich in vascular spaces.
The seminal vesicles are resistant to nearly all the disease processes that affect the prostate.
Seminal Vesicle Involvement (SVI) by prostate cancer is one of the most important predictors
for cancer progression [12, 13].
As far as innervation is concerned, the prostate is an extremely well-innervated organ. Two
neurovascular bundles are located posterolaterally adjacent to the gland and form the superior
and inferior pedicles on each side. Different studies [14, 15] have, previously, demonstrated the
importance of these nerves in penile erection, hence urologists as well as patients have put an
increasing interest in nerve-sparing surgical treatment of PCa.
Histologically, the prostate is a branching duct-acinar embedded in a fibromuscular stroma.
The epithelium has two layers: the luminal/secretory and the basal layer with some neuroen-
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docrine cells in the epithelium. The intraluminal contents of otherwise normal prostatic glands
include degenerate epithelium cells, corpora amylacea and calculi [11]. The prostate stroma
includes fibroblasts, smooth muscle, vasculature and nerves and assorted infiltrating cells (e.g.,
mast cells, lymphocytes).
2.1.2 Prostate Cancer
According to the World Health Organization (WHO), cancer is a leading cause of death
worldwide, accounting for 18.1 million new cases and 9.6 million deaths in 2018. Prostate
Cancer (PCa) is one of the most common and dreadful types of cancer. Its incidence accounts
for 1.3 million of the total cases (7.1%), ranked as the second most frequent form of cancer in
males, following lung cancer. Annually, an estimated 350,000 men die with PCa [16, 17]. These
global patterns are also backtracked in Portugal, where PCa incidence rate is around 121 per
100,000 inhabitants, the highest cancer incidence rate, both in men and in total. Of these, 22%
died in 2010 [18, 19]. As a result, PCa, as many other types of cancer, is, undoubtedly, one of
the major societal challenges in healthcare, particularly among men.
PCa growth can be characterised by two main types of evolution: slow-growing or clinical
insignificant tumours and clinical significant tumours. The former comprises up to 85% of all
prostate cancers, where the tumour is usually confined to the prostate gland. For these cancers,
the treatment is replaced with frequent monitoring [20]. The latter type of PCa - the clinical
significant tumours - progresses rapidly, metastasising from the prostate gland to other organs
and bone. Hence, radical surgery and/or radiation therapy are the treatment approaches used
to eradicate this type of tumour [21, 22].
2.1.2.1 Prostate Cancer Diagnosis
PCa has no specific presenting symptoms and is frequently clinically silent [23, 24]. Therefore,
in the past decades, the diagnostic value of screening by using different detection strategies
has come to the forefront of focus. With the introduction and widespread of screening with
serum Prostate-Specific Antigen (PSA) blood test, the number of men diagnosed with PCa has
increased, with most cases being at initial phases - localised disease - instead of advanced stages
of cancer.
The initial detection of PCa often occurs during routine medical exams. The physician has
two screening options: a PSA test and a Digital Rectal Examination (DRE). A PSA test is a
blood test aimed to measure the PSA protein level in the patient blood (in healthy men, the
PSA level is mostly below 4 ng/mL (nanograms per milliliter)). However, PSA is produced by
both normal and malignant prostatic epithelial cells, making it an organ-, but not cancer-specific
biomarker, since benign conditions - such as prostatic infection, and benign prostatic hyperplasia
[25] - may also cause its level to rise. Hence, DRE allows the physician to discern PSA clinical
significance, by detecting palpable abnormalities (e.g., nodules, asymmetry, hardness) in the
posterior and lateral regions of the prostate gland, where the majority of cancers develop [26].
Further verification of suspicious clinical or biochemical tests is based on histopathologic
verification of a prostate biopsy [27]. During a transrectal ultra-sonography-guided biopsy -
which is the currently most commonly used technique - multiple samples of prostate tissue are
collected. By extracting more samples, the higher cancer variability can be identified, avoiding
not only false negatives, but mainly distinguishing indolent prostate cancers with low risk of
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progression – which only require surveillance – from clinically significant cancers – which require
a radical therapy.
To perform the definitive diagnosis, the collected samples are observed and examined under
a microscope by a pathologist, who evaluates different histologic characteristics to determine
whether PCa is present.
2.1.2.2 Pathology of the Prostate Cancer
Most prostate cancers are of prostatic glandular origin, i.e., adenocarcinoma, though occa-
sionally, other forms of cancer, such as transitional cell carcinoma, squamous cell carcinoma
and undifferentiated carcinoma, may arise within the prostate [3]. The diagnosis of prostate
carcinoma relies on a combination of architectural and cytological features. The architectural
features are assessed at low to medium power magnification, with emphasis in spacing, size and
shape of acini. Malignant acini usually have an irregular arrangement, as well as, an irregular
contour. The groups of acini are either closely packed in back-to-back arrangement without
intervening stroma or are haphazardly distributed. In addition, while in benign acini an intact
basal cell layer is present, in prostate cancer, only a single layer of epithelium cells is present.
Therefore, the basal cell layer is a crucial feature to assess, in order to differentiate between
benign and malignant cells. Regarding the cytological features, nuclear enlargement and hyper-
chromasia, as well as, mitotic features represent the main characteristics of malignant tumour
focus [3, 11].
However, most of these features, when confined, are not entirely specific to malignancy [28]. A
pseudo-infiltrative pattern, for instance, can also be found in benign conditions, such as atrophy,
while nuclear abnormalities might be found in benign glands adjacent to inflammation areas [3].
Additionally, biopsies are regarded as difficult to resolve, not only due to the non-targeted nature
of the procedure, but also because only a few cores are available for diagnosis, where a small
number of atypical cells are not sufficient to allow an unequivocal diagnosis [29–31].
Therefore, a number of other lesions and conditions (Figure 2.3) associated to the prostate
must be considered within the context of cancer diagnosis, since they are mimickers of prostate
adenocarcinoma [28, 32, 33]. Of these, Benign Prostatic Hyperplasia (BPH), atrophy, and
Prostatic Intraepithelial Neoplasia (PIN) must be highlighted.
Figure 2.3: Lesions and structures that can simulate prostate cancer. Some of these lesions are common
differential diagnoses of prostate adenocarcinoma.
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BPH (shown in Figure 2.4) is one of the most common diseases in men from 40 years onwards,
probably due to the alterations in hormone balance. It produces obstruction to bladder outflow
and as a result of pressure effects on the proximal conducting system of the urinary tract [11].
Microscopically, BPH is characterised by the development of a number of nodules, which can
have different origins - stromal, glandular or mixtures thereof. Nodules formation is expected
to be detected more often in specimens from prostate excision, instead of from biopsies. In the
latter, these nodules are sometimes misdiagnosed as adenocarcinoma [33, 34].
Figure 2.4: BPH foci in (a) low magnification and in (b) in high magnification. The intraluminal infoldings
within the glands is charcteristic of BPH. (c) Epithelium predominant round nodule is typical in BPH. A small
sample of this nodule discovered in a biopsy could be misdiagnosed as prostate adenocarcinoma.
Atrophy - Figure 2.5 - is a common age-related benign condition, most frequently seen in
peripheral zones samples. Any subtype of atrophy is expected to show basal cells, however their
detection in some biopsies may be difficult [35] - Figure 2.6.
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(a) (b)
Figure 2.5: Low magnification of different patterns of atrophy. (a) Acinar atrophy. (b) Cystic atrophy.
Figure 2.6: Atrophic prostate carcinoma may be occasionally cystic and resembling a focus of benign atrophy.
PIN refers to multiple foci of cytologically atypical luminal cells overlying diminished number
of basal cells in prostatic ducts and is a forerunner of invasive prostatic carcinoma [11]. According
to the cytologic characteristics of its cells, PIN may be classified into low grade PIN and high-
grade PIN (Figure 2.7). The former is composed of enlarged cell nuclei, which vary in size and
have a slightly increased chromatin content. The latter is characterised by cells with large nuclei
of uniform size and prominent nucleoli - similar to those of carcinoma cells . The basal cell layer
is intact on lower grade PIN, but may present disruption in higher grade PIN [36]. PIN can be
erroneously evaluated as carcinoma or vice-versa [28], especially because there are a specific type
of carcinoma which morphologically resemble PIN, the PIN-like ductal carcinoma Figure 2.8.
The four different types of high-grade PIN are represent in Figure 2.9: tufting, micropapillary,
cribriform and flat.
When several of the above-mentioned cancer features are detected in a specimen, the diag-
nosis of prostatic adenocarcinoma can be confidently performed and a classification prognostic
grade - the Gleason Score - is reported. The Gleason score system, developed in the 1960s to
determine the aggressiveness of the cancer, is based on glandular architecture, which can be
divided into five patterns of growth or grades. Pattern 1 lesions consist of nodules of small,
well-defined glands with limited infiltration of the surrounding tissue. In contrast, pattern five
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(a) Low-grade PIN. (b) High-grade PIN.
Figure 2.7: High power view of the different PIN categories: low grade and high-grade.
Figure 2.8: Example of carcinoma of the prostate, which resembles a PIN foci. It is denominated PIN-like
ductal carcinoma.
lesions consist of layers of malignant cells with no discernible glandular differentiation and which
are widely infiltrative. Due to the fact that most tumours are highly variable, including two
or more components of these patterns, the Gleason score is, therefore, obtained by adding two
sub-grades: primary and secondary grades [37]. The primary grade is assigned to the dominant
pattern of the tumour, while the secondary is assigned to the subordinate pattern - for instance
Gleason score 4+3.
Although changes to this grading system have been implemented to this grading system,
with complementary group grades being adopted, the Gleason score system remains as one of
the most significant factors in the clinical decision-making process, not only in biopsy specimens,
but also mainly after a radical intervention is performed, being a predominant tool in outcome
prediction [38].
2.1.2.3 Prostate Cancer Treatment
After combining the results of the PSA, DRE and histological grade of the biopsy specimen,
the stage and nature of the cancer is determined. If the tumour has metastasized beyond the
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(a) (b)
(c) (d)
Figure 2.9: Schematic illustration of architectural patterns of high-grade PIN. (a) The tufting pattern shows
undulating mounds and heaps of cells protruding into the lumen. (b) The micropapillary pattern shows delicate
finger-like projections, often with bulbous tips, with or without flbrovascular cores. (c) The cribriform pattern
shows a sieve-like pattern. (d) The flat pattern shows one or two layers of cells. Adapted from [39]
prostate gland, additional tests might have to be performed, including Magnetic Resonance
Imaging (MRI), bone scan, Computed Tomography (CT) and TransRectal Ultrasound (TRUS).
These techniques provide relevant information, as far as accurate staging is concerned, both
in local and advanced disease. If a patient is found to have advanced disease with extended
involvement of surrounding structures - SVI, perineural and lymphovascular invasion - a radical
treatment would be an inappropriate approach to employ, since it would unnecessarily endanger
the patient while burdening healthcare resources [3]. In these cases, radiation therapy, androgen-
deprivation treatments and chemotherapy are the therapies of choice. Nevertheless, advanced
prostate cancer remains an incurable disease and new alternative treatments are required.
Conversely, when the diagnosis reveals localised PCa, a prostate confined tumour with no
extension to the seminal vesicles, regional lymph nodes, or distant site, he is a candidate for
surgical prostatectomy. This procedure is the standard first-line treatment with curative intent
[27, 40]. The perceived advantage of radical prostatectomy is that, the entire prostate, where
the tumour is confined, is surgically removed, aiding towards the reduction of the metastasis risk
[41]. Moreover, with the recent introduction of robotics in minimally invasive surgery, enhanced
treatment performance has been reported. Robotic assisted laparoscopic radical prostatectomy
has gained acceptance among urologists and patients, not only because it allows the surgeon
to perform complex surgical procedures with both dexterity and minimal fatigue, but mainly
because it is a less invasive procedure, diminishing operative time, blood loss and hospitalisation
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time. Suggestion of earlier improved erectile function and full sexual health, after robotic surgery
have also been reported [42, 43].
However, despite the improved results of these robotic surgeries, cancer recurrence is a
concern for men undergoing definitive treatment with curative intent for localised PCa [44]. Of
all patients treated with radical prostatectomy, approximately 35% are reported to experience a
re-emergence of PSA serum, after its total abrogation: a state known as BioChemical Recurrence
(BCR) [45, 46]. A detectable PSA level implies residual prostate tissue and, most likely, recurrent
PCa.
Considering the above, the history of BCR following surgery is highly variable, since PSA re-
lapse has different meanings according to clinicopathological features - such as: Gleason Score,
clinical stage and surgical margins status [47]. Therefore, it is of paramount importance to
treating physicians, to assess both, 1) whether BCR is going to emerge after surgery, and 2)
distinguish different biochemical recurrence based on preoperative and/or postoperative pa-
rameters. The outcome prediction information will aid towards clinical decision-making, by
implementing the golden complementary therapies, achieving, thus, a more personalised and
cost-effective treatment regimen.
2.1.3 Prostate Cancer Biochemical Recurrence Prediction
A method capable of forecasting recurrence is highly desirable, due to the complexity of
PCa disease and the associated decision-making process. Therefore, accurate estimates of the
likelihood of cancer diagnosis, stage, clinical significance, treatment success, complications, and
long-term morbidity are essential for patient counselling and informed decision-making. By un-
derstanding the most probable endpoint of a patient’s clinical course, physicians may modify
treatment and post-treatment strategies, in order to balance benefits and adverse effects of a
specific therapy. Prediction also allows patients to choose responsibly among the different treat-
ment strategies, proposed by the clinicians, which, ultimately, may improve their satisfaction
after treatment [48].
Traditionally, physician judgement is the basis for risk estimation, patient guidance, and
decision-making. However, clinicians’ estimates are often biased due to both subjective and
objective confounders [49–51]. To overcome these limitations and to obtain more accurate pre-
dictions, researchers have developed predictive tools – directed at predicting the probability of
an outcome of interest for the individual patient, without considering the effect of time [52].
Currently, clinical prognosis of PCa relies on the evaluation of histology sections under a
microscope, which allows the pathologist to determine specific tumour characteristics: Gleason
score, capsule invasion, extra capsular extension, surgical margins, SVI, lymph node invasion.
These features serve as variables in the widely-validated Kattan nomogram [53, 54] and CAPRA-
S score [55] predictive methods, considered as the best performing tools for prostate outcome
prediction after radical prostatectomy. Although these nomograms remain the most widely
used tools in clinic, as far as postoperative clinical management is concerned [41], their modest
overall accuracy is further devalued by the realisation that these tools largely fail in the most
common cohort in the modern era (mid-grade, confined disease with moderate PSA level) [56,
57]. A tendency to overestimate the likelihood of disease recurrence for lower risk patients
[55, 57] has also been reported. Hence, and in addition to these obvious generalisation and
complexity limitations [58, 59], the lack of periodic updates to reflect changes in patient and
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disease characteristics may compromise the applicability of some models to contemporary patient
populations. To illustrate this point, the surgical procedure currently employed is Robotic-
Assisted Radical Prostatectomy (RARP), as opposed to the invasive laparoscopic or open radical
Prostatectomy previously adopted (until around 2010) [60, 61]. This consideration is likely to
influence the outcome prediction.
While most prognostic efforts have focused on incorporating additional clinical variables,
which has not significantly improved predictions [62], the potential of digital histologic images
has not, yet, been fully explored. An unanswered question is whether these tools for outcome
prediction could be bypassed by novel machine learning techniques, with the power to directly
learn the prognostically relevant features in microscopy digital images of the tumour, without
prior identification of the known tissue entities [63], e.g. Gleason score, mitoses, infiltrating
immune cells, tumour budding.
Therefore, in this dissertation, and in particular in Section 2.2, emerging techniques such
as digital pathology and deep learning will be exploited in order to overcome the shortcomings
observed in the tools currently used to predict BCR. While digital pathology allows digitisation
of the histopathology image and its consequent quantitative analysis, deep learning has the power
to enhance information that cannot be perceived by the human eye. It is expected that a model
resulting from the combination of these techniques has the power to predict the occurrence of
relapse in patients treated with radical prostatectomy.
2.2 Anatomic Pathology
In this section the field of anatomic pathology will be detailed. In first place, the fundamen-
tals of anatomic pathology will be explained. Then, the role of an emerging technique as digital
pathology will be discussed and their advantages and limitations presented. Finally, approaches
using deep learning applied to histopatholgy in precision medicine will be presented and some
image classification examples for prostate cancer will be detailed.
2.2.1 Fundamentals of Anatomic Pathology
Interpreting images of tissues and cells at a resolution higher than the naked human eye is the
core of pathology (also referred to as histopathology or anatomical pathology). This medical
specialty is fundamental to studying, understanding and diagnosing disease, while providing
further insight into what is required for a successful treatment.
As disease processes occur at the molecular/cellular levels, its manifestations and mechanisms
can be observed at the tissue level using a microscope. In order to do so, several steps from the
acquisition of the sample to the final diagnosis, must be completed (Figure 2.10).
Figure 2.10: Diagram representing the histology process which allows a diagnosis to be rendered.
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The clinical histology process begins when the portion of tissue to be studied is extracted
from the patient. Several possible approaches to collect tissue are possible, including fine-
needle aspiration, needle biopsy, excisional biopsy or excision of the entirety of the lesion. The
sensitivity (i.e. the likelihood of getting the correct diagnosis) and specificity (i.e. the likelihood
of not getting the incorrect diagnosis) increase from fine-needle aspiration to excision of the
entire lesion, since the larger the biopsies, the more cellular content is preserved. Hence, the
pathologist is able to examine multiple slides from different regions of the sample. In order
to stop tissue degradation and prevent microorganisms growth, fixation of the sample, usually
accomplished with formalin, must be performed [64].
Afterwards, the tissue is physically and chemically stabilized, during the processing phase,
where water intrinsically contained within the tissue is removed, and a hardening agent (paraffin)
is infiltrated within the tissue, allowing the sample to become firm. During the embedding phase,
the sample is inserted into a block of support rigid mould. The result is a tissue block which
can now be sliced into thin sections (3-10 µm thickness). At this point, the tissue slices are
nearly invisible under a light microscope and must be stained to create contrast. The most
widely used staining method, both for diagnostic and research purposes, is Hematoxylin and
Eosin (H&E). H&E histological staining protocol differentiates structures according to their pH.
Specifically, hematoxylin, of a basic nature has affinity for acid/basophilic substances, such as
nucleic acids (DNA, RNA). In contrast, eosin has affinity for basic/acidophilic structures, of
which cytoplasm is an example. Hence, when a biological sample stained with H&E is observed
under a microscope, the cell nuclei have a blue-purple hue, whereas cytoplasms have shades in
a range from pink to red. The final result, following all of these processes, is a slide or set of
slides prepared to be visualised and analysed under a microscope by a pathologist [64–66].
2.2.2 Digital Pathology
Since the 19th century, pathologists have been using the microscope as the primary tool to
observe stained specimen on the slide glasses. They rely on the microscope, since it has the
power to provide live images at increased resolution [67]. However, after the development of the
first automated, high resolution Whole-Slide Imaging (WSI) system by Wetzel and Gilbertson
in 1999, interest in using WSI for different applications in pathology practice has steadily grown
[68, 69]. This process was catalysed by changes in imaging hardware, as well as, growth in com-
putational power accompanied by faster and increased data storage and declining computational
costs [70].
The integration of digital technologies systems in anatomic pathology departments offers
benefits, not only in terms of quality, but also efficiency [71]. WSI – the digitisation of glass
slides – produces high resolution digital images, involving relatively high speed digitisation
of glass slides of different samples (e.g. tissue sections, smears), scanning them at multiple
magnifications and focal planes (x, y and z axes) [72]. Essentially, a whole slide image consists
of a pyramid of tiled images, with various levels corresponding to a specific magnification of the
image - Figure 2.11.
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Figure 2.11: Pyramid structure representing the various resolutions that compose a whole slide image. Adapted
from [73].
Interactive software for visualisation enables the slides to be examined on a computer screen,
allowing the pathologist to freely navigate the image over a complete range of standard and in-
between magnifications and perform, therefore, tasks that have historically been carried out
with a light microscope. Digital platforms are very useful for sharing cases both locally and
internationally and to provide expertise to remote locations. Consultation for difficult cases
is, also, possible within hours instead of days to weeks for cases sent through regular mail. In
addition to this, providing a digital record of the exam to the patient, while maintaining the
original physical glass slides in archive is a tremendous advantage, as far as clinical management
is concerned. A typical digital pathology set-up is shown in Figure 2.12.
Digital slides, in contrast to glass slides, can be easily annotated and regions of interest
identified and associated to the written report. Instead of just replacing the microscope for
diagnostic purposes, digital pathology provides improved quantification analysis of histopatho-
logical images, which are tasks highly affected by subjectivity. These image analysis techniques
are more reproducible than traditional microscopy for quantitative measurements [74].
Recently, the US Food and Drug Administration (FDA) cleared the marketing of the first
WSI system for digital pathology [75]. This opens a new era for the introduction of compu-
tation components into each diagnosis process. Moreover, the digitization of high-resolution
whole slide images makes it possible to implement Computer Aided Diagnosis (CAD) system
to analyze large-scale image data, thus alleviating intra- and inter-observation variations among
pathological experts and achieving statistical conclusions across hundreds of slides [76]. Digital
pathology is regarded as the required “bridge” to apply artificial intelligence algorithms to whole
slide images which has the potential to greatly improve clinical practice.
2.2.2.1 Intelligent Digital Pathology
The promise of digital pathology is not, however, the simple transfer of an image from a glass
slide to a monitor, not even the flexibility of distribution and modification of the image, but
instead the potential to enhance the pathologist’s assessment with information and intelligence
that cannot be perceived by human examination. Moreover since most pathology diagnosis are,
currently, based on the subjective (but educated) opinion of pathologists, there is, clearly, a
necessity for quantitative image-based assessment of digital pathology slides.
Histopathology slides provide a comprehensive overview of disease and its effect on tissues,
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Figure 2.12: Digital pathology workstation. The microscope has been replaced by a high resolution computer
screen where the pathologist is able to view digitally scanned slides. Adapted from [74].
since the preparation process preserves the underlying tissue architecture [77]. As a result, a
detailed spatial interrogation (e.g. capturing nuclear orientation, texture, shape, architecture)
of the entire tumour morphological landscape and its most invasive elements can be deduced
only from a histopathology image. The additional complexity and density in these images, while
providing a wealth of information, is ideally suited to power automated computed algorithms.
The application of these algorithms is essential, not only from a diagnostic perspective, in
order to understand the underlying reasons for the rendering of a specific diagnosis (e.g. specific
chromatin texture in the cancerous nuclei which may indicate certain genetic abnormalities), but
also for research applications (e.g. to understand the biological mechanisms of the disease process
and ultimately to improve diagnosis and treatment procedures). Consequently there has been
substantial interest in the digital pathology image analysis community to develop algorithms
and feature identification approaches for automated tissue classification, disease grading and
also developing histologic image-based companion diagnostic tests for predicting disease outcome
and precision medicine [78].
Recently, a breast cancer multi-classification method using a newly proposed deep learning
model was reported [79]. Instead of just focusing on the binary classification (positive or negative
for malignancy), these authors further explore quantification to obtain different tumour sub-
classes within benign and malignant conditions (e.g. ductal carcinoma, lobular carcinoma,
adenosis, fibroadenoma,. . . ). The model used data from a large-scale dataset – BreaKHis [80]
– achieving a remarkable performance (average 93.2% accuracy), when compared to previous
reported techniques.
Coudray et al trained a deep convolutional neural network (Inception v3) to automatically
analyse lung tumour digital slides, and distinguish between lung adenocarcinoma, squamous cell
carcinoma or normal lung tissue. The deep learning model was developed using 1634 whole-slide
images available in The Cancer Genome Atlas (TCGA) [81] and tested on independent cohorts
in-house collected. Performance of the reported method was comparable to that of pathologists,
with an average Area Under the Curve (AUC) of 0.97 [82].
Moreover, a predictive tool resulting from the combination of convolutional and recurrent
architectures was recently developed to predict colorectal cancer outcome. This approach was
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based on digitised tumour tissue samples from 420 patients, without any intermediate tissue
classification. The results show that deep learning-based outcome prediction outperforms visual
histological assessment performed by human experts in the stratification into low- and high-risk
patients [83].
For automated Gleason PCa grading, Arvanati et al has recently reported a deep learning
approach to analyse prostate digital samples. A convolutional neural network was trained us-
ing detailed Gleason annotations on a cohort of 641 patients and was then evaluated on an
independent test cohort of 245 patients annotated by two pathologists. The model’s Glea-
son score achieved pathology expert-level stratification of patients into prognostically distinct
groups. Overall, this shows promising results regarding the applicability of deep learning-based
solutions towards more objective and reproducible PCa grading, in contrast with a human sub-
jective evaluation, especially for cases with heterogeneous Gleason patterns [84].
These and other recent studies [78, 85–89] suggest that state of the art deep learning tech-
niques applied to digital slide images can improve diagnostic accuracy and efficiency. It can also
provide features correlated with prognosis that a human observer cannot perceive. As these and
more studies unfold, digital pathology will undoubtedly open up new avenues for computational
exploration of individual disease tissues. With the emerging of deep learning tools, and many
available pre-trained networks, the accurate prediction of a disease outcome – which is one of
the most interesting and challenging tasks for physicians in the cancer medical field – will start
to be accomplished. Ultimately, better disease surveillance, earlier detection, more accurate and
consistent diagnosis and prognosis will create an era of truly personalised medicine.
2.3 Deep Learning
The present section is dedicated to providing insights about deep learning. Firstly the ba-
sic concepts of neural networks, the basis of deep learning, will be presented and the rest of
the chapter is dedicated to CNN, a special type of neural networks, which has been success-
fully employed in different tasks, involving processing data with grid-bases structure, especially
images.
2.3.1 Basic Concepts of Neural Networks
Deep learning offers a different perspective on feature learning and representations, where
robust, abstract and invariant features are learnt end-to-end, hierarchically, from raw data [90].
Despite being a subfield of machine learning, the key difference is on how features are extracted.
While traditional machine learning approaches depend on handcrafted engineering features,
deep learning algorithms have the power to learn a set of optimal features automatically/user-
independently. This means that these algorithms automatically perceive the relevant features
required for the solution of the problem. Deep learning is inspired by artificial neural networks
(ANN), - or simply neural networks - which in turn are biologically inspired algorithms. The
term network is named after the topology, since neural networks are represented by composing
many different layers together. A network composed of three layers connected together in a
chain structure is represented in the following figure - Figure 2.13.
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Figure 2.13: Architecture of simple neural network. It is composed of 3 layers: input layer, hidden layer and
output layer. The input layer receives the input data, a vector of N elements, in this case N = 3. The hidden
layer is composed of four units, thus the width of the model is four. The output layer computes the answer of the
network from the hidden representation.
The first layer of a neural network is called the input layer, while the last layer is called the
output layer. The former holds values of the input vector and the latter holds the final results
provided by the model. The layers between the input and output are named hidden layers. The
behavior of these layers is not directly specified by the training data i.e. the learning algorithm
must decide how to use these layers to best implement an approximation to the desired output.
The overall number of hidden layers indicates the depth of the model - thus the term deep -,
while their dimensionality (i.e. number of neurons) determines the width of the model.
The fundamental component of neural networks is the artificial neuron, named node or unit.
Just as in biological neurons, an artificial neuron takes in a vector of inputs x= [x1 x2 x3 ... xn]
each of which is multiplied by a specific weight w = [w1 w2 w3 ... wn] and an activation function
φ is applied. The output of the neuron is expressed as:
y = f(x) = φ(x ·w+ b) (2.1)
where b is the bias term. Weights and biases are the neuron’s parameters, and their values
are determined in the process of learning. A schematic representation of an artificial neuron is
shown in Figure 2.14. The activation function decides whether a neuron should be activated or
not, i.e. whether the information that the neuron is receiving is relevant or whether it should be
ignored. The purpose of the activation function is to introduce nonlinear properties, allowing
the network to learn from highly complex functions, instead of just computing linear functions
(e.g. the linear transformation of the input by the weights and biases).
As far as activation functions are concerned, the most commonly used types are Sigmoid,
Tanh, Rectified Linear Unit (ReLU) and Leaky ReLU. However, ReLU is the function adopted
in the majority of the deep learning models, since it is computationally economical compared
to the remaining alternatives and has proven to successfully work in a wide range of different
cases.
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Figure 2.14: Schematic representation of an artificial neuron, where
∑
= x ·w+ b.
As far as the information flow is concerned, different models are distinguished in neural
networks: feedforward and recurrent neural networks. In feedforward networks, information
flows from the input to the output through the different network layers and without feedback
connections. If those connections are present and intermediate outputs are redirected back to
previous layers or stored for later use, the network is called recurrent. Since only feedforward
networks are used in this study, the following sections concern only this type of networks.
2.3.2 Training a Neural Network
Training a neural network, i.e. learning the values of the parameters (weights and biases) is
the essential part of deep learning and is accomplished by solving an optimisation problem. In
order to solve this optimisation problem, gradient-based algorithms are used and the weights of
the model are updated using the backpropagation algorithm [91].
The first phase is the forward-propagation, which occurs when the network is exposed to
the training data and these cross the entire neural network in order to calculate the predictions
(labels). In detail, the input data is passed through the network in such a way that all the
neurons apply their transformation to the information they receive from the neurons of the
previous layer and send it to the neurons of the next layer. When the data has crossed all the
layers, and all its neurons have made their calculations, the final layer will be calculated with a
result of label prediction for the original input samples.
Afterwards, a loss function - often called the objective function, cost function, or simply
error - must be chosen. This function is used to evaluate to what extent the output is correctly
predicted, i.e. it quantifies how good or bad the prediction result is, when compared to its known
label. Ideally, the cost function would be zero, meaning that there is no divergence between the
estimated value and the expected value. Typically, for classification problems the cross-entropy
loss is the most commonly used loss function. Once the loss has been computed, this infor-
mation is propagated backwards in order to improve the model predictions. Hence, the name
of the algorithm: backpropagation. Starting from the output layer, that loss is propagated to
calculate the gradient of the loss function with respect to each neuron of weights or parameters.
Thereafter, these parameters - weights - are updated in the opposite direction of the gradient of
the loss function. Different variants of gradient descent algorithm have been proposed, includ-
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ing Stochastic Gradient Descent (SGD), Adaptive gradient (Adamgra) and Adaptive moment
estimation (Adam). The Adam optimiser - derived from the Adamgrad - is very similar to the
SGD, however, instead of maintaining a single learning rate for all weight updates it computes
and uses individual adaptive learning rates for different parameters from estimates of first and
second moments of the gradients.
This process is then repeated for each example of the dataset and the weights of the inter-
connections of the neurons will be gradually adjusted until good predictions are obtained, i.e.
until a minimal loss error is reached.
2.3.2.1 Hyperparameters Tuning
In addition to the weight parameters defined within the network, deep learning algorithms
also require additional parameters to carry out the learning process. These hyperparameters
highly influence the algorithm performance and must, therefore, be wisely selected.
In order to update the weights of the model, a number of samples from the training dataset
must be used to calculate the error: this hyperparameter is denominated batch size. The batch
size is a hyperparameter that defines the number of samples to go through before updating the
internal model parameters. The batch size has an effect on the resource requirements of the
learning process. A large batch size (sometimes equal to the entire dataset) allows computational
boosts, but at the expense of more memory for the training process. A small batch size is
advantageous since it prevents the training process from stopping at local minima, but it is also
considerably more prone to noise during the error calculations. The optimal size will depend on
many factors, including the available memory capacity, as well as the size of training dataset.
Once the loss gradient has been estimated, the derivative of the error can be calculated and
used to update the weights of the network through:
wnewi = woldi −γ ∗
∂L
∂wi
(2.2)
where wnewi and woldi are the current and previous weights respectively, ∂L∂wi is the gradient
of the loss function (in this one-dimension case, it will be the first derivate of loss function with
respect to only one weight) and γ is the learning rate. The learning rate controls at which pace
the weights are updated. The optimal value for the learning rate depends on the problem under
study. In general, if it is too large, the learning process is fast - since big steps are being made
at each iteration, however, in this case, the minimum value is likely to be missed, making it
almost impossible for the algorithm to converge. Conversely, if the learning rate is small, small
advances will be made at each iteration, improving the likelihood of smoothly reaching a local
minimum. Nevertheless, this can cause the learning process to be too slow.
Finally, the training process must be repeated several times until a good or good enough set
of model parameters is discovered. The total number of iterations of the process is bounded by
the number of complete passes through the data after which the training process is complete.
This is referred to as the number of epochs. The optimal number of epochs can be reached
using, for instance, a strategy of imposing a condition, e.g. epochs stop when the error is close
to zero.
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2.3.2.2 Datasets, Overfitting and Regularisation
The ultimate goal of a neural network is to have a model which performs well both on the
data used to train and the new, previously unseen data on which the model will be used to make
predictions. The ability to perform well on previously unobserved inputs is called generalisation.
In order to accomplish such purpose, firstly, the dataset should be divided into three partitions
- training set, validation set and test set. The training dataset is the sample of data used to fit
the model (find the weights and biases, as previously described). The validation set is used to
evaluate a given model and fine-tune the model hyperparameters, providing a proxy measure of
model accuracy during the optimisation process. If the performance of the model on validation
data is satisfactory, then its performance can be measured on the test dataset, which the model
has never seen before this point. The results obtained with the test dataset are the gold standard
used to evaluate the model. This strategy enables a fair evaluation of the model by measuring
how well it generalises on new data unseen by the model.
According to not only the total number of samples, but also the actual developed model,
different dataset split ratios might be employed. 60:20:20 or 75:15:10 are common ratios for
training, validation and test, respectively. However, many times, instead of splitting the data
into three different groups, they are only divided into two datasets - train and test. After
this, the train dataset is split into X% to be the actual train set and the remaining (100-X)%
is determined to be the validation set, where X is a fixed number (e.g. 80%). The model is
then iteratively trained and validated on these different sets. This procedure is known as cross-
validation (the basic form of cross-validation is k-fold cross-validation). The prime reason for
the use of cross-validation, instead of the conventional validation, is related to insufficient data
samples, making infeasible to partition these into separate training, validation and test sets.
Additionally, the cross-validation procedure ensures that an unbiased model is produced.
The result of running the trained-validated model on the test set, will ideally be an accurate
model which is able to generalise well on new data, i.e. provides a good fit to the data. A
model with these characteristics is neither underfit nor overfit. An underfitting model is not
able to adequately capture the underlying structure of the data and performs poorly in both
the training and test sets. Effective procedures to avoid underfitting can easily be employed:
for instance, increasing the capacity of the model by changing its structure adding more layers
and/or more nodes to layers. Conversely, a model is overfitting if it finds a solution that is too
tightly linked to the training examples. Instead of capturing the dominant trend of the data, it
learns too many patterns and characteristics from the training data, which are not required for
the output prediction.
Avoiding overfitting can be achieved through different regularisation methods, such as ob-
taining more data or using data-augmentation approaches to artificial generate more samples
from the training data. L2 regularisation algorithm is, however, the most popular technique im-
plemented to reduce overfitting. Specifically, a penalty term - called weight decay: (λ)- is added
to the loss function on the training set to reduce the complexity of the learned model. This
value controls the penalisation added to the model, based on the size of the weights allowing the
model to build solutions based on multiple features, while limiting its flexibility and improving
its generalisation capacity.
Additionally, dropout, which consists of ignoring (or dropping) a random fraction of units
and their corresponding connections, has the power to reduce interdependent learning among
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neurons, forcing the model to avoid relying excessively on particular set of features, thus being
extensively used to avoid overfitting.
2.3.3 Evaluation Metrics
An essential element of deep learning algorithms is the selection of the right evaluation
metrics. A suitable metric allows the comparison of the performance of different algorithms,
while limiting the bias in the reported results. It is standard to provide multiple metrics,
nevertheless, algorithms are generally evaluated according to, among others, the function they
were aimed at.
Specifically for classification tasks, the confusion matrix - Figure 2.15 - is an intuitive and
easy manner to report results, which displays all possible outcomes regarding the class prediction.
Figure 2.15: Confusion matrix for a binary classifier.
The most commonly used metrics can be calculated based on the confusion matrix, such
as accuracy (Equation 2.3), precision (Equation 2.4), recall or sensitivity (Equation 2.5) and
specificity (Equation 2.6).
Accuracy = TP +TN
TP +TN +FN +FP (2.3)
Precision= TP
TP +FP (2.4)
Recall = TP
TP +FN (2.5)
Specificity = TN
TN +FN (2.6)
Although confusion matrix can be applied both to the classical binary model and to the multi-
class model, the application of the above referred metrics is restricted to binary classifiers. F1
Score - Equation 2.7 - is the weighted average of precision Equation 2.4 and recall Equation 2.5.
Therefore, this score takes both false positives and false negatives into account. Intuitively, it
is not as easy to understand as accuracy, but F1 score is usually more useful than accuracy,
especially in presence of uneven class distribution.
F1score= 2× Precision×Recall
Precision+Recall (2.7)
Cohen’s Kappa score is an evaluation statistic that takes into account how much agreement
would be expected by chance and is commonly computed in the presence of unbalanced datasets.
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Its values range from 0 - no agreement, other than what would be expected by chance - to 1 -
complete agreement. This coefficient can also take negative values, which implies that there is
no effective agreement between the set of values or the agreement is worse than random.
2.3.4 Convolutional Neural Networks (CNN)
CNN are a variant of neural networks that use convolution operations in, at least, one of the
hidden layers. These networks are specifically designed to process large-scale images or sensory
data in the form of multiple arrays [92]. The impressive performance of CNN and its great success
in the field of computer vision and pattern recognition [93], such as for visual recognition [94],
image retrieval [95] and scene annotation [96] has propelled its use and continuous development
and optimisation. The general CNN architecture is represented in Figure 2.16: it is composed
of different types of layers: Convolutional layers, Pooling layers and Fully Connected layers -
these last especifically for classification tasks.
Figure 2.16: Basic CNN architecture composed of convolutional layers, followed by subsampling, e.g. pooling,
and fully connected layer. The width of the model increases as the depth grows. Adapted from [97].
The real advantage of deep learning, especially for image recognition, comes from convolu-
tional layers, since it is responsible for capturing features from the images, which is the essence
of a CNN. The first layers usually obtain low-level features (like edges, lines and corners) while
the others get high-level features (like structures, objects and shapes).
The process made by convolutional layers can be decomposed into two phases: (i) the con-
volution step, where a fixed-size window, named kernel, is convolved over the image. Due to
the fact that these kernels are spatially smaller than the input image, a parameter named stride
controls the sliding of the kernels through all the image, defining a region of interest. For in-
stance, by defining a stride equal to one, kernels are moved one pixel at a time, while for a stride
equal to two, kernels advance two pixels at a time, as they are being slid through the input. (ii)
The processing step uses the pixels inside each window as input for the neurons, which finally
perform the feature extraction from this specific region. Formally, in the latter step, each pixel is
multiplied by its respective weight, generating the output of the neuron. Thus, only one output
is generated concerning each region defined by the kernel. This iterative process results in a new
image (or feature map), generally smaller than the original one, with extracted visual features.
An illustration summarising this process is presented in Figure 2.17.
Many of these features extracted from the convolutional layers are very similar, since each
kernel may have common pixels, generating redundant information. Therefore, convolutional
layers are usually followed by pooling layers, which are aimed at simplifying or reducing the
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Figure 2.17: Convolution process with a kernel of 3× 3 and a stride of 2. The kernel slides through the input
and at each position an element-wise multiplication and addition is performed, originating the feature map of size
3× 3.
spatial dimensions of the information derived from the feature maps, thus, preventing over-
fitting and improving its computational efficiency. Pooling layers are, hence, also known as
downsampling layers. Specifically, in this type of layer a filter (and also a stride of the same
size) is applied to the input feature map and the pooling function replaces the input with a
summary statistic of the nearby feature parameters, creating a condensed feature map. The
most commonly used pooling methods include the average pooling and the max pooling [98].
The former applies an average function to the input feature map, while the latter employs a
maximum function (Figure 2.18). In all of these cases, pooling makes the network less sensitive
to small translations of the input images, since it considers whole regions instead of separate
input values, providing emphasis to the feature weight regardless of its location.
After several convolution and pooling layers, the CNN are, generally, finalised with a fully
connected layer for classification tasks. This type of layer takes all neurons in the previous layer
and connects them to every single neuron in its layer. Fully connected layers perform like a
traditional neural network and contain about 90% of the parameters in a CNN. Its function is
to take as input the output of the previous pooling layer, and produce an N dimensional vector,
where N corresponds to the number of possible predicted classes within the model.
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Figure 2.18: Schematic illustration of a 2× 2 pooling function. Each region of the input data is replaced by its
maximum or average value, for max and average pooling, respectively.
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3 MATERIALS AND METHODS
This chapter aims to describe the materials and methods used to ultimately develop the deep
learning models used to predict PCa and BCR. Firstly, a description of the data, as well as its
collection and the used processing techniques are presented. Then, the two different classification
models are discussed. The first model is used to predict the following classifications: normal
versus tumour versus high-grade PIN, while the second model concerns the prediction of PCa
non-recurrence versus PCa recurrence.
3.1 Data Description
A retrospective pilot study was conducted randomly choosing 200 prostate cancer cases
treated at the Champalimaud Clinical Center, between 2014 and 2017. The cohort comprises
cases of men who, after being diagnosed with prostate cancer, were subjected to a radical
surgery. Follow-up of these patients during the following two years after intervention, were also
fully carried out at Champalimaud Clinical Center. Patients who received preoperative hormone
or radiation therapy were excluded from this study. Postoperative treatments are only applied
after the occurrence of relapse, thus if patients undergo additional therapies, it does not affect
the research outcome. It is worth noting that no changes to the clinical standard procedures
were introduced. This study was also approved by the Ethics Committee of Champalimaud
Foundation. In order to obtain the above mentioned approval, several documents had to be
written. These are included in the Appendix section.
For the first classification task, the 200 prostate cases were included. However, due to
insufficient information regarding follow-up or other complications, 22 patients were excluded,
resulting in a total of 178 cases for the second classification task.
3.2 Data Collection
As opposed to radiological images, which are generated within a computer, facilitating its
posterior processing and analysis, histopathology slides images have to be digitised in order to
become digitally available. Before the digitasion of the selected clinical cases, several stages,
illustrated in Figure 3.1, had to be completed.
Firstly, H&E tissue sections corresponding to the whole prostate piece were retrieved from the
pathology archive (around 40 glass slides per patient). Typically, the tumour was not restricted
to one specific area, but instead distributed through different glass slides, since as demonstrated
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by several authors [99–101], prostate cancer tends to be a multifocal disease. Thus, instead of
selecting several images per patient - a laborious task - only the slides containing the index lesion
were chosen for each of the patients. This procedure was applied because the index lesion - the
largest tumor focus within the prostate - and its associated characteristics (namely, the grade
and the presence or absence of extracapsular extension, lymph node invasion), generally drive
the prognosis [101, 102]. Afterwards, the selected glass slides were digitised in a whole slide
scanner (IntelliSite Ultra Fast Scanner, Philips [103]) and manually verified and downloaded
from the Phillips Software Platform.
Figure 3.1: Necessary stages completed in order to transform the glass slide images into digital format.
For the first model, a total of 217 tissue sections were included, derived from 200 patients
who underwent a radical prostatectomy, with a median of one tissue slide per patient and an
interquartile range of 1 to 3. For the second model, 192 slides were included, derived from 178
patients, producing a median of one tissue slide per patient and an interquartile range of 1 to 3.
3.3 Whole Slide Image Processing
Image processing is of paramount importance, especially in the field of medical imaging. It
allows enhancement and optimisation of the image characteristics such as sharpness and contrast.
Hence, not only human viewers have an improved perception of the information contained within
images, but also automated image techniques are provided with improved input images, offering
both more sophisticated performance in distinctive tasks and the possibility of implementing
methods which would be impracticable by alternative means.
3.3.1 Colour Normalisation
The appearance of the histological stains (e.g. H&E staining used in this study) often suffer
from large variability [104]. While pathologists can effectively cope with staining variability,
the performance of automated computational systems can be hampered by colour and intensity
variations. Such variations in digital pathology images may be attributed to a number of factors,
including specimen preparation and staining protocol inconsistencies (e.g. varying temperature
of solutions), variations in fixation characteristics, inter-patient variation, and the scanner used
to digitise the slides [104]. Despite the use of standardized staining protocols and automated
staining machines which improve staining quality by yielding a more accurate and consistent
staining, eliminating all the underlying sources of variation is not feasible [105]. Therefore, colour
normalisation is an essential procedure to avoid discrepancies within the colours and intensities
of the sample images.
Various colour normalisation approaches have been proposed in the literature [106–109].
However, these proposed algorithms have different shortcomings: they have been solely focus-
ing on standardisation of patch images which contain only small regions of the whole image,
disregarding the importance of colour relation between structures; they take fixed predefined
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target colour images or use manual thresholds to establish the target model, making it harder
to reproduce results.
These limitations were surpassed in [110], which presents a method, named Structure-
Preserving Color Normalization (SPCN). SPCN works by replacing the colour basis of a source
image - to normalise - with that of a pathologist-preferred target image (with the ideal colour
and contrast), while still maintaining its original stain concentrations. The respective source
code is available in [111] and was changed and adapted to be used in this dissertation.
3.3.2 Patching Approach: Patching the whole slide images
One typical whole histopathology section can be scanned to yield an image of a size larger
than 100,000 × 100,000 pixels (usually up to 2 gigabytes with a JPEG compression scheme -
default of the IntelliSite Ultra Fast Scanner software by Philips [103]), containing more than 1
million descriptive objects. Due to the inherent large-scale property of a histopathology image
dataset, the feature extraction model needs to be both time and memory efficient, and the
learning algorithm should be designed to be able to extract as much information as possible
from these large images.
Although deep learning algorithms, specifically CNN, have the power to perform classification
tasks [94], the extremely large size of a single histopathology image makes it unrealistic and
impractical to construct a model taking these very large images as input. Based on this fact,
and on all of the histopathology classification articles reviewed [87, 112–115], both classification
frameworks presented in this study adopt a patch sampling technique to leverage CNN activation
features of much smaller local patches, so that essential local details are preserved.
Hence, instead of providing the raw original whole slide image as input to the network, all
the histopathologic images were patched. However, before this process, and only due to memory
and time restrictions, the images had to be downsampled (approximately a 10× downsample).
Afterwards, each histopathology image was divided into a set of non-overlapping smaller sub-
images, i.e. square patches, with a size of 256× 256 pixels. The resulting sub-images, the
patches or tiles, were in RGB, exactly like the original whole slide images. Of these generated
RGB patches, some are composed solely of white background (for example in the corners and
borders of the tiles, since the tissue tends to have an irregular format, in comparison to the field
of view, which is rectangular). Thus, these did not contain any type of relevant information
or features to be extracted and were discarded through an entropy-based elimination approach.
In detail, this technique computes the entropy for each patch and eliminates it if the value is
smaller than a specific threshold, which is empirically determined based on the intrinsic dataset
characteristics.
3.3.3 Annotations
The generated patches - a total of 160,689 - were individually visualised and manually an-
notated by the author and reviewed by both the author and the Champalimaud Clinical Center
expert pathologist (Prof. Dr. Antonio Beltran). Three different classes were distinguished: the
first class was benign tissue which included both healthy glands and glands with low-grade PIN
(class 0: negative); the second class was composed of tumour tissue (class 1: positive); and
the third class comprises high-grade PIN instances (class 2: PIN). It is noteworthy, that when
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high-grade PIN and malignant tissue were present within the same patch, the classification was
always considered to be positive for tumour (i.e. class 1: positive).
As far as BCR prediction is concerned, the ground truth corresponded to the non-recurrent
(class 0: negative) or recurrent (class 1: positive) condition which was obtained from the clinical
information from each patient. A recurrence state was defined as a PSA value equal or greater
than 0.2ng/dl, during the two years after the surgery date. From the 44,515 generated patches
for this experiment, all the patches corresponding to a non-recurrent case were annotated as neg-
ative, while the patches corresponding to a recurrent case were annotated as positive. Table 3.1
summarises all of the information above.
Table 3.1: Number of cases, slides and generated patches for the two models developed in this study.
Model 1: PCa Classification Model 2: PCa BCR Prediction
Number of Cases 200 178
Number of Slides 217 192
Number of Patches 160,689 44,515
3.4 Deep Learning and CNN
Deep learning enables the extraction of multiple feature levels from data directly without
explicit definition [116, 117]. CNN are the most successful deep learning models for processing
multi-dimensional array data, such as colour images, being as a result the most common type
of model used in digital pathology. Various CNN configurations have been developed AlexNet
[118], VGGNet [119], GoogLeNet [120], Inception v3 [121]. Some of these architectures have
repeatedly been shown to be successful for image recognition tasks and became standards in
the field of digital histopathology [82, 112, 113, 115, 122, 123]. However, Inception v3 was the
architecture chosen to be used in this study, since it has been shown to achieve great classification
performance, especially for outcome prediction [67, 82, 83].
3.4.1 Inception V3 Implementation
In 2014, GoogLeNet, developed at Google, took first place in the 2014 ImageNet competition
for classification and detection challenges [120]. Its main contribution was the development
of an inception module, the basic unit of GoogLeNet. Within an inception module a series
of convolutions at different scales are performed and subsequently concatenated into a single
output vector. In order to save computation time, 1x1 convolutions are used to reduce the input
channel depth. For each cell, a set of 1x1, 3x3 and 5x5 filters which learn to extract features at
different scales from the input are used.
In order to further optimise the inception module, the same researchers developed a more
efficient inception cell - Inception v3 [121]. Despite being beneficial in terms of their expres-
siveness and ability to extract features at a larger scale, convolutions with large spatial filters
(such as 7x7) are computationally expensive, and were, thus, factorised into asymmetric convo-
lutions: 1x7 and 7x1 convolutions. Additionally, 5x5 convolutions were replaced by two stacked
3x3 filters, providing a cheaper representation, while still maintaining the model performance.
Auxiliary outputs were also added to the primary network, since they were found to benefit the
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performance of the model, converging at a slightly better value than the same network architec-
ture without an auxiliary part. The addition of auxiliary outputs also has a regularizing effect
on the network, preventing overfitting.
As far as implementation is concerned, the Inception v3 architecture [124] was implemented in
a platform specially developed and optimised for medical imaging applications, named NiftyNet
[125]. NiftyNet is built using the TensorFlow [126] within the Python environment. It provides
not only a high-level deep learning platform with components optimised for medical imaging
applications (image segmentation, classification, regression, generation), but it also grants the
tools to define and efficiently execute computational pipelines on hardware resources.
All of the deep learning models were executed in the Computational Cluster available at
the Champalimaud Foundation. The machine specifications used to train, validate and test the
developed algorithms are presented in Table 3.2.
Table 3.2: Hardware and Software specifications of the compute machine.
CPU Intel (R) Xeon (R) CPU E5-2620v3 @ 2.40GHz
RAM 128GB DDR4 2133MHz
OS CentOS release 7.7.1908 - kernel 3.10.0-1062.1.1.el7
GPU NVIDIA TITAN X Pascal
CUDA CUDA 10.1
Python v3.6.8
Tensorflow v1.10.0
NiftyNet v0.5.0
3.4.2 Model I: PCa Classification
Given a patch as an input, the goal of this task was to classify the image into one of the
three groups - negative for tumour (class 0), positive for tumour (class 1) and PIN (class 2).
In order to do so, the data was randomly split into two datasets: training, validation and test,
accounting for 90% and 10% of the total data respectively. It is worth noting that all tiles
of the same patient were not separated, but were instead, associated as a whole to either the
training/validation or test datasets to prevent contamination between the datasets and biases
results. The resulting dataset is highly imbalanced, as shown in Table 3.3, specially class 2
which is around 45× less represented than class 0.
Table 3.3: Class representation for the dataset used to develop model I.
Classes Number of Samples
Class 0 108,523
Class 1 49,735
Class 2 2,431
Firstly, an hyperparametresation of the network was performed using the training and val-
idation data. In order to do so, some network parameters were modified in order to optimise
the hyperparameters - specifically, learning rate, weight decay, number of epochs and batch size.
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To find the appropriate parameters, diagnostic plots - which show loss over training epochs
during training - were used to investigate how the different values of learning rate, batch size
and number of epoch impact the rate of learning and learning dynamics of the model.
The learning rate (lr) is the most important hyperparameter to optimise, so that it balances
the quality of the final solution with the training time required to achieve such outcome. A
starting learning rate of 0.0001 was used, however, since this value made the network adjust
too slowly, i.e. taking a long time to converge, a higher learning rate value (lr = 0.01) was
used. This value was found to be too large, since the model appeared to converge too quickly,
yet to a suboptimal solution. Therefore, a learning rate value of 0.001 was adopted because it
represented a good trade-off value.
As far as weigh decay is concerned, its values range between 0.0 (no penalty) and 1.0 (full
penalty). If the decay is high, the model will underestimate the weights and underfit the problem.
Conversely, if the decay is too small, the model will be allowed to overfit the training data.
Although a value of 0.01 tends to be high for most models, it was successfully adopted, allowing
a well enough data fitted model.
The number of epochs is the number of times the entire training data is shown to the model.
It plays an important role in how well the model fits the train data. Different values were
tested, but 20,000 was the selected final value, given that the model converged and did not
overfit. Values higher than 20,000 epochs deteriorate the model, since it, somehow, started to
diverge and the accuracy and loss improvements were not significant.
Concerning the batch size, it is recommended to use batch sizes in powers of 2 (for better
memory optimisation). Values of 16, 32, 64 and 128 were tested. Batch sizes of 16 and 32
originated a noisy loss function. Although a value of 128 was found to be better in terms of loss
behavior, there were not enough memory resources to use this value. A batch size of 64 was
selected, since a trade-off between time/memory resources and performance were required.
As far as training and validation are concerned, a k-fold cross-validation was used to reliably
evaluate the model performance. The data was split into 5 partitions (k=5), instating 5 identical
models and training each one of 4 (k-1) partitions, while evaluating on the remaining partitions.
Figure 3.2 shows a schematic representation of a cross-validation procedure. The partition
corresponding to the best model, i.e. the model which delivered an optimal performance was
ultimately used on the test dataset. The performance of the models was assessed by using both
visual tools - TensorBoard - and quantitative metrics - confusion matrix, accuracy and Cohen’s
Kappa statistic.
Model 1 was applied to both non-normalised and normalised (Subsections 4.2.1 and 4.2.2,
respectively). These experiments provide interesting insights in terms of model behaviour, when
visual improved images are provided.
3.4.3 Model II: PCa Biochemical Recurrence Prediction
Model 2 aims to classify each patch into one of the following groups: PCa non-recurrent (class
0) PCa recurrent (class 1). Due to the fact that relevant prognostic features are obtained from
the characteristics of prostate adenocarcinoma [38], instead of using all the generated patches,
only the tumour positive patches were considered for this second model. Majority voting among
the predicted patch-wise labels of a given patient was used to categorize a case as non-recurrent
or recurrent.
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Data was divided into two datasets: training/validation (90% of the total dataset) and test
(10% of the total dataset), while ensuring that tiles of each patient were contained only within
one of the datasets. This procedure was applied due to the fact that an outcome per patient
was intended to extract. and by having patches of the same patient split into different datasets
this was not possible.
The class distribution for this dataset is presented below in Table 3.4.
Table 3.4: Class representation for the dataset used to develop model II.
Classes Number of Cases Number of Images
Class 0 132 26,806
Class 1 46 13,640
Before training, an hyperparametresation was performed. Different combinations of values
for learning rate, weight decay, number of epochs and batch size were tested.
Concerning the learning rate, a value of 0.001 showed to deliver the best results. Smaller
values were also tested, however they did not improve the performance of the model. The weight
decay was chosen to be 0.0001, since it is within the range of values used for regularisation.
Given the complexity of the task in question, a higher value of epochs was chosen, specifically
35,000. Values of 15,000 and 60,000 were also tested. While the former value was too small,
not allowing the model to converge, the latter yielded no significant improvements in terms of
accuracy and loss, when compared to the value of 35,000.
Similarly to model I, the batch size was kept equal to 64, since it was the higher value
that allowed training the model without failing due to lack of available memory. However, it is
expected that higher batch size values could produce a noiseless model.
These above-mentioned parameter values were used for the training/validation and testing.
Similarly to model 1, a 5 fold cross-validation approach was implemented Figure 3.2. From the
5 different partitions, the one with the best performance was selected to be used in the test
dataset. In addition to the metrics used for model 1 - confusion matrix and Cohen’s Kappa
statistic - other metrics including accuracy, specificity, sensitivity, precision and F1 score were
also used to assess the performance of this recurrence prediction model.
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Figure 3.2: Overview of a k-fold cross-validation example, where k = 5. The entire dataset is partioned into 5
groups of samples, called folds.
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4 RESULTS
The major results are presented in this chapter. A brief discussion demonstrating the impor-
tance of image processing is, firstly, presented. Afterwards, the results from model I, both for
non-normalised and normalised images are presented, as well as the results from model II. All
the data analysis was performed using Python and all the developed code is available at [127].
4.1 Importance of Image Processing
Variations in colour and intensity of H&E stained histological slides are granted features,
when visualising this type of images. In order to improve consistency across the histologic
images dataset, and ultimately improve classification effectiveness, a state of the art colour
normalisation techniques was applied. An illustration of a whole slide image before and after
normalisation is shown in Figure 4.1. Instead of only improving the image contrast, the original
image structure i.e., the ratio between the different color concentrations, is preserved.
The patching approach phase is fundamental, as far as histological image analysis based
on deep learning are concerned. A schematic illustration of the patch approach is presented
in Figure 4.2. As can be seen, the whole slide image originates several patches that are only
composed of white background. At the end of the entropy-based elimination process, which
intended to discard these background patches, a mean of 741 patches per whole slide image
was obtained, with a minimum of 143 and a maximum of 1304 patches per slide. Regarding
the annotation phase, examples of the different classes considered are represented in Figure 4.3.
All of these procedures culminated in the establishment of a database of prostate annotated
histology images comprising 217 slides of 200 different cases.
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(a) Target image. (b) Original image.
(c) Normalised image.
Figure 4.1: Illustration of the performance of the colour normalisation technique. Given a selected target image
(a), the original image (b) is transformed, yielding an image with improved contrast (c), i.e. the normalised
image.
Figure 4.2: Schematic representation of the performed patching approach. The whole slide image generates
multiple smaller images, which are used to feed the neural network.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.3: Different classes distinguished during the annotation process. (a), (b) and (c) are instances of benign
tissue corresponding to class 0; (d), (e) and (f) are instances of malignant tumour corresponding to class 1; (g),
(h) and (i) are instances of high-grade PIN corresponding to class 2.
4.2 Model I: PCa Classification
This multi-class task was performed for both non-normalised and normalised images. In
order to accurately perform a comparison between the different approaches, the parameters of
the network were kept constant and in the following setting:
Table 4.1: Learning parameters used to develop model I, both for non-normalised and normalised images.
Training Parameter Value
Learning rate 0.001
Weight decay 0.01
Epochs 20,000
Batch size 64
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4.2.1 Non-normalised images
Training and validation was performed following a 5-fold cross-validation in order to select
the model yielding the best performance and use it for the test phase. Concerning quantitative
evaluation parameters, since the data has an unbalanced nature (refer to Table 3.3), in addition
to accuracy, Cohen’s Kappa coefficient was also calculated. The values of the above mentioned
metrics, resulting from the 5-fold cross-validation are shown in Table 4.2.
Table 4.2: Evaluation metrics calculated for 5 folds during the training/validation phase, concerning non-
normalised images. The highlighted row corresponds to the fold yielding the best performance model.
Accuracy Cohen’s Kappa Coefficient
Fold 1 0.94 0.85
Fold 2 0.93 0.84
Fold 3 0.92 0.81
Fold 4 0.93 0.81
Fold 5 0.93 0.85
The accuracy and loss, obtained from the best model - i.e. model produced by the fold 5 -
are visualised in Figure 4.4 and Figure 4.5.
Figure 4.4: Accuracy progression for model I with non-normalised images. The blue line corresponds to training
curve and the orange line to validation curve.
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Figure 4.5: Loss progression for model I with non-normalised images. The blue line corresponds to training
curve and the orange line to validation curve.
The final results, i.e the results for the test dataset, using the model obtained from fold 5,
are presented below. The confusion matrix obtained for this three-class classification problem
is illustrated in Figure 4.6. Instead of having the two entries found in the typical binary classi-
fication task, the confusion matrix has three entries, which correspond to the negative (class 0),
positive (class 1) and PIN (class 2) conditions.
Figure 4.6: Normalised testset confusion matrix, corresponding to the results of model I for non-normalised
images.
The accuracy value and the Cohen’s Kappa coefficient were also determined and are presented
in Table 4.3.
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Table 4.3: Final values of accuracy and Cohen’s Kappa coefficient yielded by the non-normalised images test
dataset.
Evaluation Metric Value
Accuracy 0.94
Cohen’s Kappa Coefficient 0.85
In order to further quantify the quality of the model’s prediction, regarding each of the
classes at stake, and mainly because the classes are highly unbalanced, a binary analysis was
performed. This is accomplished by treating the data as a collection of binary problems, one for
each class. Some metrics which would only be defined for binary classification tasks can, hence,
be determined.
Table 4.4: Different evaluation metrics calculated for the non-normalised images test dataset.
Recall Specificity Precision F1 Score
Class 0 0.97 0.88 0.94 0.96
Class 1 0.90 0.96 0.92 0.91
Class 2 0.07 0.99 0.59 0.13
4.2.2 Normalised images
Model I results, yielded by the normalised images are presented below. The values obtained
both for accuracy and Cohen’s Kappa coefficient, during the training/validation phase, with a
5-fold cross-validation strategy implemented are shown in Table 4.5.
Table 4.5: Evaluation metrics calculated for 5 folds during the training/validation phase, concerning normalised
images. The highlighted row corresponds to the fold yielding the best performance model.
Accuracy Cohen’s Kappa Coefficient
Fold 1 0.92 0.82
Fold 2 0.92 0.80
Fold 3 0.91 0.77
Fold 4 0.93 0.82
Fold 5 0.94 0.85
The graphics shown in Figure 4.7 and Figure 4.8 corresponded to the accuracy and loss
respectively, obtained for the model which produced the best performance - in this case the
model resulting from fold 5.
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Figure 4.7: Accuracy progression for model I with normalised images. The blue line corresponds to training
curve and the orange line to validation curve.
Figure 4.8: Loss progression for model I with normalised images. The blue line corresponds to training curve
and the orange line to validation curve.
The results for the test dataset are presented below. The confusion matrix obtained for this
three-class classification problem is illustrated in Figure 4.9.
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Figure 4.9: Normalised testset confusion matrix, corresponding to the results of model I for normalised images.
In Table 4.6, the final values of both accuracy and Cohen’s Kappa coefficient are summarised.
Table 4.6: Accuracy and Cohen’s Kappa Coefficient evaluation metrics for the testset, concerning normalised
images.
Evaluation Metric Value
Accuracy 0.93
Cohen’s Kappa Coefficient 0.85
In addition to accuracy and Cohen’s Kappa coefficient metrics, Table 4.7 presents the recall,
specificity, precision and F1 score, which were calculated by treating the data as a collection of
individual binary problems, one for each of the three classes considered.
Table 4.7: Different evaluation metrics calculated for the normalised images test dataset.
Recall Specificity Precision F1 Score
Class 0 0.96 0.90 0.93 0.94
Class 1 0.91 0.95 0.93 0.92
Class 2 0.06 0.99 0.56 0.10
4.3 Model II: PCa Biochemical Recurrence Prediction
Model II was aimed at differentiating between non-recurrent cases and recurrent cases, based
on the tumour positive normalised patches (corresponding to the instances of class 1 in the
previous model). The learning parameters used for this task are summarised in Table 4.8.
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Table 4.8: Learning parameters used to develop model II.
Training Parameter Value
Learning rate 0.001
Weight decay 0.0001
Epochs 35,000
Batch size 64
The accuracy and Cohen’s Kappa coefficient metrics for the training/validation phase, with a
5-fold cross-validation implementation, are shown in Table 4.9. The highlighted row corresponds
to the fold which produced the best performance model.
Table 4.9: Accuracy and Cohen’s Kappa coefficient evaluation metrics calculated for the training/validation
phase of model II.
Accuracy Cohen’s Kappa Coefficient
Fold 1 0.81 0.00
Fold 2 0.80 0.00
Fold 3 0.56 0.00
Fold 4 0.65 0.00
Fold 5 0.49 0.00
The graphics corresponding to the accuracy and loss of the model produced by fold 1 are
represented in Figure 4.10 and Figure 4.11, respectively.
Figure 4.10: Accuracy progression for model II. The blue line corresponds to training curve and the orange line
to validation curve.
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Figure 4.11: Loss progression for model II. The blue line corresponds to training curve and the orange line to
validation curve.
Despite the fact the algorithm failed to learn and, thus, to correctly perform the proposed
task, the whole deep learning pipeline was completed. Therefore, in Figure 4.12 the confusion
matrix of the testset results is presented. Since this is a binary classification task, the confusion
matrix follows the classical arrangement: it has two entries, corresponding to the negative class
(class 0) and the positive class (class 1).
Figure 4.12: Testset confusion matrix, corresponding to the results of model II.
Majority voting was not applied to the results provided by the model, since all the patches
were labeled as negative, which would result in classifying all the cases as negative, i.e. non-
recurrent cases.
Based on the confusion, matrix some evaluation metrics were calculated - these are repre-
sented in Table 4.10.
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Table 4.10: Different evaluation metrics calculated for the model II test dataset.
Evaluation Metric Value
Accuracy 0.60
Cohen’s Kappa Coefficient 0.00
Recall 0.00
Specificity 0.00
Precision 0.00
F1 Score 0.00
4.3.1 Resampling of the Original Dataset
Given the results obtained for the highly unbalanced BCR dataset, a resampling of the data
was performed in order to understand if the justification for the model to fail was, somehow, re-
lated to the dataset class distribution. The characteristics of the new dataset, i.e. the resampled
dataset are summarised in Table 4.11.
Table 4.11: Balanced dataset distribution.
Class 0 Class 1 Total
Number of Cases 46 39 85
Number of Patches 13,326 13,326 26,648
Using the same learning parameters as for BCR original dataset, model II was trained and
validated on the resampled dataset, producing the accuracy and loss curves represented in
Figure 4.13 and Figure 4.14, respectively.
Figure 4.13: Accuracy progression for model II with the resampled dataset. The blue line corresponds to
training curve and the orange line to validation curve.
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Figure 4.14: Loss progression for model II, with the resampled dataset. The blue line corresponds to training
curve and the orange line to validation curve.
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The application of image processing techniques to the H&E images allowed, as can be per-
ceived in Figure 4.1, an improved contrast and also a decreased visual variability of the resulting
tissue image dataset. Additionally, although pathologists are specifically trained to be able
to cope with variations across slide images, the standardisation process allows an easier and
straightforward annotation procedure, since the different structures can be easily differentiated.
This is of extreme importance, specially when dealing with huge amounts of data, providing
a faster labeling process, which within deep learning schemes takes a substantial amount of
time. All of the collection and processing procedures - i.e. data curation - culminated in the
establishment of an annotated database of prostate histological slides, with the corresponding
clinical metadata. Apart from being used in this study to develop the deep learning models, the
potential of this database is immense. A wide range of hypothesis can, now, be exploited and
clinical questions regarding prostate cancer diagnosis, prognosis may be addressed.
In order to discern about the role of normalisation, i.e. if the improved visual quality of nor-
malised images perceived by humans is translated into a better performance of a computer based
algorithm, model I was developed both for non-normalised and normalised images. The results
showed that little difference existed between the performance of the two models. Analysing,
firstly, the training phase results, the values of the determined evaluation metrics for all the
5-fold cross-validation are very similar, both accuracy and Cohen’s Kappa coefficient, specially
for the best performance model (both yielded by fold 5). The value of the Cohen’s Kappa
coefficient is, however, smaller than accuracy, since this coefficient takes into account the fact
that the different classes are highly unbalanced (refer to Table 3.3). Conversely, since the ac-
curacy metric uses information of all class distributions of the dataset, is inherently sensitive
to unbalanced distributions. Therefore, if class distribution varies - as from non-normalised to
normalised test dataset - measures of the accuracy performance also change, even though the
underlying fundamental performance of the classifier does not.
As far as accuracy and loss progression are concerned, it can be observed that, both curves
follow the same pattern. The accuracy curves - both for non-normalised and normalised images,
Figure 4.4 and Figure 4.7 respectively - show a convergence tendency for a value around 90%.
The loss progress represented in Figure 4.5 and in Figure 4.8 respectively for non-normalised
and normalised images, reveal a reduction of error after some iterations, with a convergence
pattern. The combination of great accuracy with low loss accomplished by model I, corresponds
to the best case scenario, when training deep learning models, specifically, CNN, since only small
errors on few data are made.
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The same results are also conveyed by the test dataset. While for the non-normalised images
an accuracy value of 94% was obtained, a value of 93% was achieved by the model based on
normalised images. The exact same value of Cohen’s Kappa coefficient, 85%, was achieved by
both models. Although it was expected that the normalisation procedure would improve the
performance of the CNN, this did not happen. Hence, it can be concluded that for this specific
problem, network and learning parameters, the normalisation procedure does not improve the
inherently learning capacity of the developed model. This also reveals the robustness of the
architecture Inception v3, for the applied learning parameters, which allows the model to cope
with input, quantitatively and qualitatively different. However, it cannot be extrapolated that
the same conclusions would be obtained if different networks architectures or even different
learning parameters were implemented. For instance, if nuclei segmentation or tissue partitioning
were the aimed tasks, higher resolution characteristics and features would be assessed, and it
would be likely that the model would struggle to cope with variations in image appearance and
staining, causing the algorithm to have a large number of errors for slightly differently stained
images from the same structure.
Owing to the fact that both types of images provide similar models, as far as performance is
concerned, only the detailed analysis of model I for normalised images will be discussed, since
the same conclusions can be applied to the non-normalised images based model. Regarding
the learning phase, it can be seen from Figure 4.7 and Figure 4.8 that the curves, although
well behaved - i.e. showing a convergence pattern - present some noise. This is related to the
maximum value of batch size allowed to be used (64), given the memory resources available. A
higher value of batch size could deliver noiseless and more stable curves.
Figure 4.9, which summarises the results of the testset, is illustrative of the behaviour of
the model for the different classes. Firstly, it can be noticed that the model fails to identify
instances belonging to class 2 (only 6% are well classified). Instead it mainly identifies these
images as instances belonging to class 0 (69%). This behaviour was, somehow, expected since
this class was underrepresented as compared to classes 0 and 1. Consequently, the model is not
able to learn specific PIN characteristics and features in order to accurately differentiate this
category. Data augmentation, for class 2 could have been implemented, in order to increase the
number of PIN instances, through different operations such as random rescaling, horizontal flips,
padding, perturbations to brightness, contrast, and colour, as well as random cropping, which
are commonly used to train large neural networks. However, the number of artificial generated
images would be at least 20× higher than the real initial images and this type of process
could highly influence and suppress or even change the intrinsic characteristics of the original
class 2 images, thus, it was not implemented. Concerning classes 0 and 1, the model performs
exceptionally well, achieving 96% and 91% of accurately classified instances, respectively. These
values correspond to the recall, i.e. the effectiveness of the model when classifying positive labels
(refer to Table 4.7). Specificity indicates how effectively a classifier identifies negative labels and
its value is almost 100% for class 2, which is explained by the fact that only few instances are
being correctly classified as positive and, therefore, all the remaining are classified as negative.
The values of the same parameter for classes 0 and 1 are also high, which means that negative
labels are correctly identified. Precision, a measure of exactness, provides insight into what
proportion of positive predicted images are actually positive. For classes 0 and 1, the precision
value is large (93%), meaning that there is a great chance of images to be whether negative
or positive for tumour (the most represented classes of the model). Class 2 precision value is,
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conversely, low - 56% - indicating that there are many false positives, considering the number
of true positives. The above analysed metrics, similarly to accuracy, are sensitive to changes
in data distributions. However, F1 score, a combination of precision and recall, measures the
effectiveness of classification both for balanced and unbalanced class distributions. The values of
this parameter to classes 0 and 1 are high - 94% and 92% - demonstrating the model’s capacity
to successfully discriminate tumour negative and positive instances, respectively. The same is
not valid for class 2, for which the model achieves only a F1 score of 10%, indicating, once more,
that the model is not capable of successfully learning the characteristics of the PIN class.
Given that the model was developed based on data, whose labeling was perform by humans
(the author and the Champalimaud expert pathologist), and still achieved high results, means
that the quality of the labeling of the data is also outstanding. Otherwise, the garbage in, garbage
out thumb rule, commonly used in machine learning would dictate a poor performance of the
model, since it would be difficult for the model to produce any kind of good results regardless
of how good the labeling is.
In clinical practice it is of paramount importance to maximise the recall, since it essentially
corresponds to the probability of detection of the studied characteristic. In this case, it is
imperative not to miss positive patches, and in order to do so, class 1 recall should become
100%. Despite the fact that this value is only 91%, it still presents potential to be improved,
which can be accomplished by increasing the number of instances belonging to this class, in
order to balance the dataset and allow the algorithm to learn more characteristics of tumour
positive class images. Regarding the PIN class (class 2), it was included in this classification
problem due to the fact that specific types of cancer are, structurally, similar to high-grade
PINs, being significant to differentiate between them. This type of distinction may gain extra
interest and relevance if this classification model is used in images derived from biopsies, instead
of from radical prostatectomies. In biopsies, differentiating between PIN and tumour might
be an arduous exercise, since limited tissue slides are collected and the context of surrounding
architecture and environment which are used to discern the possible classification of the structure
is, most of the times, not accessible. It is expected that increasing the number of PIN instances,
and therefore the images belonging to class 2, would lead to an improved result, enabling the
application of the developed model to clinical practice.
Bearing in mind that (i) state of the art accuracy values for classification of histopathology
images are above 90% and (ii) values for Cohen’s Kappa coefficient above 80% are defined as
almost perfect, it is possible to confidently conclude that model I performance is extremely
good. An user interface to implement the developed model into clinical care has already been
considered. The implementation of such methods provides improved efficiency and consistency,
greatly benefiting current clinical practice.
The goal of model II was to differentiate between non-recurrent and recurrent cases, through
the analysis of tumour positive patches. This type of prediction, as previously mentioned, cannot
be performed by humans and different techniques mainly based on nomograms are used to predict
the occurrence of relapse. Considering the training/validation results of the presented model, it
is possible to conclude that the algorithm was not able to identify features that could translate
the desired output. Figure 4.10 and Figure 4.11 clearly demonstrate that the model does not
have the ability to successfully complete the referred task. The former figure, corresponding to
the accuracy progress during training, reveals a curve that is kept almost constant through the
whole learning process (in this particular case 35,000 epochs was chosen to be learning end point).
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Although higher than 50% - the chance of achieving a correct prediction on a binary classification
problem - the accuracy value corresponds approximately to the class 0 representation percentage
(about 60% to 70%). Additionally, the progress of the loss curve reveals an excessively high loss
value and absence of not only a decreasing pattern, but also a convergence point, results that
corroborate the prediction incapacity of the model. Based solely on the behaviour of model II
during the training phase, it can be stated that it fails to learn from the data. Consequently, the
Cohen’s Kappa coefficient holds a value of zero - meaning that there is no agreement between the
predicted and true labels. After achieving these results, several attempts were made to change
the hyperparemeters, but even after experimenting different hyperparameters combinations, the
underlying result did not change.
Nevertheless, the pipeline was finished and the ”best” performing model during train-
ing/validation was further used in the test dataset. Here, the term ”best” refers simply to
the model which had more instances belonging to class 0, producing, hence a misleading higher
accuracy score. The confusion matrix - Figure 4.12 - produced by the testset results, as expected,
demonstrates the model lack of success in predicting BCR. With this evaluation scheme, it is
possible to note that the model classifies all the entries as belonging to class 0 and therefore, the
more images with class 0, apparent better results would be delivered. The evaluation parameters
summarised in Table 4.10 demonstrated, once more, what has been said about model II. All
metrics hold a value of 0, except accuracy. This is derived from the fact that the accuracy metric
in this case does not provide adequate information on a classifier’s functionality: for instance,
in a simple situation, if a given dataset includes 5% of minority class examples and 95% of
majority examples, by classifying every example to be a majority class example, an accuracy
of 95% will be produced. Taken at face value, 95% accuracy across the entire dataset appears
superb; however, on the same token, this description fails to reflect the fact that 0% of minor-
ity examples are identified. The same circumstances lead the accuracy value of the developed
model to achieve a 60% of accuracy, even though the model completely fails to deliver correct
predictions regarding the input images.
Moreover, in order to understand if the unbalanced dataset nature of model II was responsible
for the poor performance produced, a resampling of the dataset was performed. The resulting
dataset was composed of, approximately, the same number of images for the two classes (refer to
Table 4.11). From Figure 4.13 and Figure 4.14 it can be concluded that, the model, once more
failed to learn from the data provided. Therefore, the class distribution of the dataset does not
influence the results of the developed model for BCR prediction.
Concluding, although model II has failed, and its derived results are poor, several assump-
tions can be drawn. In first place, it is interesting to note that the same architecture - Inception
v3 - and data, i.e. same images, processed all in the same way, were applied to the two addressed
problems. While for the first problem, regarding PCa classification, a model delivering state
of the art was accomplished, the model obtained to predict BCR was not successful. This is a
characteristic of deep learning based approaches, many unknowns take part in producing the
final output. An essential consideration, when using deep learning is that models need to be
built with significant information, and one of the main justifications for models to fail is lack of
data. In this particular case, model II was developed using about 40,000 images, which albeit
being a quite high number, it is not close to the hundred of thousand of images employed for
model I, not even from the millions of images that are used for ImageNet to accomplish a wide
range of different classification tasks. Specifically in a medical environment, this is presented as
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an enormous obstacle: the inability to obtain not only data, but mainly enough data.
Not having the right data and/or not all the necessary data to be able to answer the initially
asked question may also have been one of the problems for the failure of the BCR prediction
model. As already mentioned, the biochemical relapse prediction assignment is extremely com-
plex. This is reflected on the few methods used to predict this condition, which are yet not
as accurate and generalisable as intended. Moreover, these prediction techniques assume the
integration of a variety of clinical characteristics that are recognised as having an important
role on the BCR condition. Hence, it is likely that the proposed approach is too simple for the
biochemical relapse prediction assignment. For instance, the introduction of clinical features,
such as pre-operation PSA, Gleason score, SVI, extra capsular extension and margins status into
the model might be advantageous, providing it with more information, which could, ultimately,
be correlated to the extracted features of the histopathology images. Finally, most machine
learning problems follow the “No Free Lunch” theorem which states that there is no one model
that works best for every problem. The assumptions of a good model for one domain may not
hold for another, so it is possible that the Inception v3 architecture may not be the best choice
to the BCR prediction assignment.
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6 CONCLUSIONS
PCa is one of the most common types of cancer, affecting millions of men, every year. The
associated diagnosis and prognosis are highly depended on the histopathological analysis of the
prostate specimen. The advent of digital pathology and the unfolding of diverse studies sug-
gesting state of the art deep learning techniques applied to medical images, reveal the potential
of combining these two techniques in order to achieve earlier detection, more accurate and con-
sistent diagnosis and prognosis and consequently create an era of truly personalised medicine,
which will ultimately improve patient’s lives.
In this sense, the present dissertation intended to explore the potential of deep learning algo-
rithms, specifically CNN, to harvest relevant data from histological images of the prostate. The
ability of CNN to automatically learn appropriate representations of the data, using relatively
little preprocessing and its independence from prior knowledge and human effort in feature
design is a major advantage, when comparing these techniques to other image classification
hand-engineered algorithms. CNN architectures are based on simple yet powerful concepts, and
their mathematical implementation makes their design successful in a wide range of tasks.
The architecture of different networks were studied, yet Inception v3 was the choice to
develop two different models. While the purpose of the first model was to classify images as
negative or positive as far as the presence of prostate cancer was concerned; the second was
intended to predict the occurrence of BCR.
However, in order to successfully develop deep learning models data curation is a major
phase that must be completed. Therefore, an annotated database of histopathology images,
composed of 200 prostate cancer cases who received surgical treatment, was established. Data
annotation - performed both by the author and a pathologist – was a fundamental part of the
deep learning projects, since it provided the setup for training the implemented architecture
from scratch allowing it to accurately function.
The results obtained revealed state of the art accuracy for model I - 93% - and poor accuracy
for model II - 60%. Given these results, one can conclude that model I could assist pathologists
in the task of reviewing images obtained from radical prostatectomies and detect positive slides,
for them to further review. In order to do so, the following is suggested: the development of an
interface that can automatically perform all the data processing procedures and give an output
per whole slide image - negative if all the patches are negative for tumour and positive if there is
one, and only one, positive patch. Additionally, the performance shortcomings of model II would
have to be surpassed. This could be accomplished by including prognostic clinical parameters or
use all the patches both positive and negative, instead of only using the tumour positive patches.
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Negative patches may, perhaps, have some kind of characteristic which can be correlated to the
BCR prediction.
For future work, some limitations of the presented study should be addressed, in particular,
the limited memory resources available, which dictated the downsampling of the whole slide
images, decreasing their resolution and possibly the accuracy of the developed algorithms. Ad-
ditionally, the developed models should be tested with external data, i.e. data from external
institutions or data from repositories, such as TCGA. These types of experiments and tests
will ultimately provide stronger evidence of the effectiveness and generalisation of the developed
models.
Finally, bearing in mind all of the above mentioned, it is possible to concluded that the
proposed goal for this project were fulfilled. Given the potential of the developed database and
models, strategies to assure its continuous and increasing valorisation were also discussed. The
application of these strategies will ensure the provision of a broader and more useful information
for the definition of more consensual diagnosis and prognosis.
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A.1 Ethics Committee Submission Documents
Study Summary
Title: Prostate Cancer Biochemical Recurrence Prediction using Machine Learning Analysis
of Multiparametric Magnetic Resonance and Histopathology
Acronym: ProBCR
Portuguese Synopsis:
Neste estudo pretende-se utilizar me´todos de aprendizagem automa´tica para analisar imagens
me´dicas de ressonaˆncia magne´tica multiparame´trica e de histopatologia digital, de pacientes
com cancro da pro´stata tratados com prostatectomia radical. O objetivo e´ verificar se estes
me´todos sa˜o capazes de recolher informac¸a˜o das imagens que consiga prever a possibilidade
de recorreˆncia bioqu´ımica de cancro da pro´stata. A capacidade de identificar indiv´ıduos com
essas caracter´ısticas teria um impacto cl´ınico importante.
English Synopsis:
The purpose of this study is to use machine learning methods to analyse medical images of
multiparametric magnetic resonance and digital pathology, of prostate cancer patients treated
with radical prostatectomy. It is intended to verify if these methods can extract relevant
image information to predict the occurrence of biochemical recurrence of prostate cancer after
surgical treatment. The ability to identify individuals with such characteristics would have
an important clinical impact.
Type pf study:
Pilot retrospective study for patients already treated (with request for Informed Consent
waiver).
Involved Institutes/Collaborations:
No other institutes will be involved or collaborations established for this study.
Funding:
No funding required for the execution of this project.
CR/CCC participation units/groups:
CR - Computational Clinical Imaging Group
CCC – Urology Unit
CCC - Radiology Department
CCC – Pathology Unit
Number of patients:
120-200
Study duration:
1 year
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Research Protocol
Project Title
Prostate Cancer Biochemical Recurrence Prediction using Machine Learning Analysis of Multi-
parametric Magnetic Resonance and Histopathology
Investigators and Affiliation
Principal Investigator: Nickolas Papanikolaou, PhDa
Co-Investigators: Ana Gaiva˜o, MDb, Anto´nio Beltran, MD, PhDb; Jorge Fonseca, MDb
Project Executors: Carolina Seabra, MSc Studenta; Mo´nica Silva, MSc Studenta
a Champalimaud Research, Lisbon, Portugal
b Champalimaud Foundation, Lisbon, Portugal
1 Background
1.1 Prostate Cancer and Biochemical Recurrence
Malignant neoplasms of the prostate, hereafter referred to as prostate cancer (PCa), usually originate in the
glandular tissue. While these cancers are often indolent, there is a subset of men who are diagnosed with highly
malignant prostate cancers associated with poor prognosis1.
The disease poses a substantial public health burden worldwide: PCa is the most frequently diagnosed cancer
among men in over-half of the countries in the world, and it is the leading cause of oncological death among
men in 46 countries, with nearly 1.3 million new cases and 359000 associated deaths estimated for this year of
20182. Selecting the optimal treatment for each patient is an important aspect in order to improve PCa clinical
management.
Currently, PCa early clinical detection depends on the prostate specific antigen (PSA) serum level, as well
as on the examination of multiparametric magnetic resonance imaging (mpMRI) that provides information on
both morphological and physiological properties of tissues3. Nevertheless, its definitive diagnosis is based on
histopathologic biopsy verification4. The pathologist attributes a prognostic predictor, the Gleason Score. This
scoring system, developed in the 1960s, consists of two sub-grades: primary and secondary grades. The former is
assigned to the dominant pattern of the tumour or the most common cell morphology, while the latter is assigned
to the subordinate pattern. Each of the grades is defined on the scale from 1 to 5, according to the cellular and
architectural appearance of recognisable glands, with lower grades corresponding to more normal prostate tissue5.
In clinical practice, different treatment options are currently available for PCa patients, including active surveil-
lance, adjuvant therapy, radiation therapy and radical prostatectomy (RP). The latter is, yet, the standard
first-line curative procedure for the management of localised PCa4,6–9, given the effectiveness of this therapeutic
option for such patients7,10,11. It consists of surgically removing the prostate gland, the seminal vesicles, and
surrounding tissue sufficient to ensure a negative surgical margins12.
Besides being measured at the diagnostic stage, PSA serum level, an organ- but not cancer-specific biomarker, is
also indispensably assessed in follow-up after a curative treatment, such as RP13,14. Its previous elevated value
is expected to reach undetectable levels within 4 weeks after RP15.
However, despite technical improvements in the surgical procedures for PCa treatments, there is a significant risk
of cancer recurrence after therapy7. Of all patients undergoing RP, between 25% and 35%7,16–20 present a rising
detectable serum PSA level greater than 0,2 ng/ml21 - a state known as biochemical recurrence (BCR).
Approximately two-thirds of BCRs occur within the first 2 years of surgery22 and earlier BCR may be associated
with increased risk of prostate cancer-specific mortality23. BCR is widely used as an end point to assess RP
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efficacy, and it most likely represents the first sign of progression after surgery24. In some cases, its occurrence
precedes cancer recurrence, representing, simultaneously, a marker of metastatic progression and PCa-specific
mortality6.
Thus, for men with PCa and candidates to receive curative treatment, such as RP, the risk of development of
cancer recurrence after treatment is a main concern. Hence, an early BCR identification and treatment is of
paramount importance to improve long-time survival.
1.2 Prediction of Biochemical Recurrence
One of the most acute needs in PCa management, nowadays, is higher precision in prediction of clinical outcomes
for more effective decision-making25.
Nomograms and probability graphs for BCR prediction following surgery have been constructed, such as the
D’Amico et al. risk stratification scheme26, the Stephenson et al. nomogram27, and the Cancer of the Prostate
Risk Assessment (CAPRA) score28. All of these models rely on commonly available clinical and histopathological
variables, such as preoperative PSA, clinical stage, and biopsy Gleason score6,29. Although these nomograms
have been internationally validated, only a few of them have predicted the probability of BCR with more than
70% accuracy30–32.
Recent BCR prediction tools are incorporating mpMRI-derived variables to improve the outcome of the prediction
models. This imaging modality has been investigated as promising way not only for detecting and staging
the cancer, but also for risk stratification, since it is considered the most sensitive and most specific imaging
technique to detect and characterise the clinical aggressiveness of the PCa tumours7, which is related with BCR
occurrence. On the other hand, including histopathologic digital images from the prostate resection might improve
the accuracy of the tools which rely on biopsy information, since biopsy is not representative of the whole prostate
lesion33,34.
Given the current used methods, alternative approaches such as logistic regression models, support vector ma-
chines, classification and regression trees analysis, and artificial neural networks, are believed to further improve
sensitivity, specificity and accuracy of the referred tools35. The combination of such computational approaches
with data harvested from different imaging modalities might enhance BCR prediction for prostate cancer.
2 Project Aim
This study aims to develop classification models that can predict prostate cancer BCR.
One of the approaches will use imaging features that can be harvested from preoperative mpMRI data, while the
other will be based on histopathologic prostate resection digital images. Both approaches will use preoperative
clinical variables acquired in the current diagnostic protocol, and implement machine learning methods to predict
BCR occurrence in patients who underwent radical prostatectomy for prostate cancer treatment.
For the former, the main objective would be to provide an initial evaluation, before a curative attempt, to
patients diagnosed with PCa. Meaning, at the diagnostic time-point, and without the need of performing a
biopsy, indirectly evaluate the biological aggressiveness of the patient’s tumour - in the sense of relapsing or not
after a RP surgery. The latter aims to take advantage of a novel way of analysing pathologic information, which
is digital pathology. It presents several functionalities, such as the extraction of quantitative data, resulting from
direct measurements like dimensions, number of pixels, or intensities, which cannot be accomplished with optical
microscopy.
We hypothesise that there are different mpMR and histopathology digital image characteristics capable of differ-
entiating between BCR-free and BCR patients, after undergoing radical prostatectomy.
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3 Materials and Methods
3.1 Study Type
This pilot study will analyse retrospective data: preoperative clinical parameters, standard-of-care mpMR images
routinely acquired at the diagnostic phase of prostate cancer management - without any changes to the clinical
and imaging protocols -, and digital pathology images acquired from radical resection of the patients with PCa -
without any changes to the clinical procedure.
3.2 Study Population
Regarding the histopathological imaging based approach, all patients who underwent radical prostatectomy at
Champalimaud Clinical Center between 2016 and 2018 (200 patients) will be considered to be included in this
study. As for the mpMR imaging based approach, all patients examined with preoperative prostate mpMRI and
treated with radical prostatectomy at Champalimaud Clinical Centre, between 2016 and 2018 (approximately
120-150 patients) will be considered in the inclusion of this study. The imaging protocol used in these patients
was the oncological standard of care in the management of prostate cancer.
Patients who received pre- or postoperative hormone or radiation therapy will be excluded from this study.
3.3 Patient Data Collection and Protection
The collection of the retrospective data will be performed by institutional radiologists, urologists and pathologists,
reviewing, retrospectively, the clinical information of patients, and selecting the patients to be included on the
analysis.
Regarding the mpMRI approach, the researchers and collaborators responsible for the project execution will
be responsible for the retrieval of the patients’ radiographic images from the institution Picture Archiving and
Communication System (PACS) and de- identification of images and databases containing patient identifiable
information.
For the histopathologic approach, the researcher responsible for the project execution will be responsible for
the retrieval and scanning of the histopathologic digital images and de-identification of images and databases
containing patient identifiable information.
For both procedures, a password protected encrypted file with the de-identification correspondence keys will be
saved in a password protected workstation located within a room accessible only with the door key.
3.4 Data Processing, Analysis and Model Development
The collected data will be de-identified to ensure patient anonymity.
Imaging preprocessing methods will be explored for the enhancement of the image data. Machine learning
algorithms will be applied to the set of data for the processing phase, since it is a powerful technique for recognising
patterns on medical images36. This will allow the description of visible and invisible textures to the human eye in
a numerical and objective way - known as radiomics features37 -, followed by the model development to classify
PCa patients based on their BCR occurrence. Lastly, model evaluation will be based on the outcome prediction
performance.
4 Request for waiver of Informed Consent
The development of models to predict BCR will require the analysis of prostatectomy specimens digital images,
mpMR images, as well as preoperative clinical information. The results of this study will be stronger by working
with a larger number of data, and discarding the patients already imaged or followed in the past would delay the
results. We will only use anonymised data from patients already treated, whose retrospective data analysis could
benefit the treatment of future patients.
This pilot study might make possible the prediction of BCR, and this could improve the patients’ treatment
and/or prognosis control.
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Informed Consent Form
This informed consent form is directed to patients who underwent radical prostatectomy.
The title of the research project is “Prostate Cancer Biochemical Recurrence Prediction using Ma-
chine Learning Analysis of Multiparametric Magnetic Resonance and Histopathology”.
This is a national project developed by Champalimaud Foundation.
Principal Investigator
Nickolas Papanikolaou
Introduction and Purpose
The Urology Unit and Computational Clinical Imaging group together with the Pathology and
Radiology Clinical Service from Champalimaud Foundation, have a research project on biochemical
recurrence following radical prostatectomy. The main purpose is to use multiparametric magnetic
ressonace (mpMR) imaging and histopathology to predict prostate cancer biochemical recurrence
after radical prostatectomy surgical treatment.
After hearing the procedure information, we present a brief description about the study. Please read
carefully the following information. After reading, if you have any doubts, do not hesitate to ask
them to your physician so they can be clarified.
Type of intervention
This study did not change the clinical and therapeutic procedure previously defined. We solely ask
you the permission for the researcher to use your mp-MR and histopathologic images to apply new
analysis methods.
Patient selection
All patients with prostate cancer who were examined through mp-MR imaging and underwent radical
prostatectomy, at the Champalimaud Foundation may be included in the study. In case you received
any type of pre- or postoperative treatment, your enrolment in this study should be disregarded.
Voluntary participation
The participation in this study is voluntary. The patient is free to choose whether or not to partici-
pate. The patient’s choice did not change the quality of the treatment he received. In case you want
to participate, you are free to dismiss at any moment, needing only to inform your urologist.
Procedure
The participation in this study did not involve additional procedures. The follow-up of the patient
was done according with the institution’s standard of care of oncological patients.
Risks
No risks were defined for the participation on this study.
Benefits
The results of this study can potentially improve the treatment of prostate cancer patients who
underwent radical prostatectomy.
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Appendix
Compensations
Your participation in this study will not have any additional costs for you. No compensation, either
monetary or other, will be given to you for your participation in this study.
Confidentiality
All the data collected during this study will be confidential and protected. In case you participate, a
unique identifier will be assigned to you and only your physician will know that this unique identifier
corresponds to you.
Sharing of the results
The results of this study, ensuring the correct de-identification, can be shared on scientific meetings
and published in scientific journals.
Right to refuse or dismiss
Your participation in this study is your choice. Whether you chose or not to participate in this study
the quality and the treatments that you receive will not change. In case you decide to dismiss, you
can do it at any moment by contacting your urologist.
Contacts
In case you have any questions in the future, either during or after this study, please contact the
urologist in charge:
Dr. Contact
Name of the patient
Signature of the patient Date (dd/mm/yyyy)
Name of the urologist
Signature of the urologist Date (dd/mm/yyyy)
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Formula´rio de Consentimento Informado
Este formula´rio de consentimento informado e´ dirigido a pacientes com cancro da pro´stata tratados
atrave´s de prostatectomia radical.
O t´ıtulo do projeto de investigac¸a˜o e´ “Prostate Cancer Biochemical Recurrence Prediction using Ma-
chine Learning Analysis of Multiparametric Resonance Imaging and Histopathology”.
Este projeto e´ nacional e foi desenvolvido pela Fundac¸a˜o Champalimaud.
Investigator Principal
Nickolas Papanikolaou
Introduc¸a˜o e Propo´sito de Estudo
A Unidade de Urologia e o grupo Computational Clinical Imaging, em conjunto com os Servic¸os Cl´ınicos
de Patologia e Radiologia da Fundac¸a˜o Champalimaud, esta˜o a realizar um estudo em pacientes com
neeoplasia maligna da pro´stata. O objetivo principal e´ desenvolver um modelo, baseado em imagens
de ressonaˆncia magne´tica multiparame´trica (RM-mp) e histopatologia da pro´stata, que permita prever
recorreˆncia bioqu´ımica, apo´s tratamento com prostatectomia radical.
Apo´s a informac¸a˜o sobre o processo lhe ter sido prestada oralmente, apresenta-se em seguida um
resumo escrito das caracter´ısticas deste estudo. Por favor leia com atenc¸a˜o esta informac¸a˜o. Se, apo´s
ler esta informac¸a˜o, tiver quaisquer du´vidas, por favor coloque-as ao seu me´dico para que possam ser
esclarecidas.
Tipo de intervenc¸a˜o
O estudo na˜o alterou os planos cl´ınico e terapeˆutico, previamente estabelecidos. Pedimos-lhe, somente,
permissa˜o para que os investigadores possam avaliar novos me´todos de ana´lise de imagem referentes
a`s imagens de RM-mp e de histopatologia.
Selec¸a˜o de participantes
Todos os doentes com cancro da pro´stata que foram examinados atrave´s de RM-mp e tratados com
prostatectomia radical na Fundac¸a˜o Champalimaud, podera˜o ser inclu´ıdos no estudo. Caso tenha
realizado outro tipo de tratamento pre´- ou po´s-operato´rio, na˜o devera´ ser inclu´ıdo neste estudo.
Participac¸a˜o volunta´ria
A participac¸a˜o neste estudo e´ totalmente volunta´ria. A escolha de participar ou na˜o neste estudo cabe
unicamente ao doente. O facto de escolher ou na˜o participar neste estudo na˜o vai alterar a qualidade
dos servic¸os e tratamentos que recebe. Caso escolha participar, o doente podera´ desistir a qualquer
momento, bastando para isso informar o seu me´dico urologista.
Procedimentos
Na˜o foram realizados procedimentos adicionais como resultado da participac¸a˜o no estudo. O segui-
mento do doente enquadrou-se no seguimento normal de doentes oncolo´gicos realizado pela Instituic¸a˜o
de origem.
Riscos
Na˜o foram definidos riscos de participac¸a˜o neste estudo.
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Appendix
Benef´ıcios
Os resultados do estudo teˆm o potencial de melhorar o tratamento de doentes com cancro da pro´stata
tratados atrave´s de cirurgia radical da pro´stata.
Compensac¸o˜es
A sua participac¸a˜o neste estudo na˜o tera´ quaisquer custos adicionais para si. Na˜o lhe sera´ dada
nenhuma compensac¸a˜o, moneta´ria ou outra, pela sua participac¸a˜o neste estudo.
Confidencialidade
Todos os dados recolhidos durante este estudo sa˜o mantidos estritamente confidenciais, em suporte in-
forma´tico protegido. Se decidir participar neste estudo, ser-lhe-a´ atribu´ıdo um nu´mero de identificac¸a˜o
u´nico. Apenas o seu me´dico sabera´ que esse nu´mero u´nico corresponde a si.
Partilha de resultados
Os resultados do estudo, devidamente anonimizados, sera˜o partilhados em reunio˜es cient´ıficas e publi-
cados em revistas cient´ıficas.
Direito a recusar ou desistir
A sua participac¸a˜o neste estudo e´ uma escolha exclusivamente sua. O facto de escolher ou na˜o
participar neste estudo na˜o vai alterar em nada a qualidade dos servic¸os e tratamentos que recebe.
Caso escolha participar podera´ desistir a qualquer momento, bastando para isso informar o seu me´dico.
Contatos
Caso lhe surjam quaisquer questo˜es futuras, seja durante a sua participac¸a˜o neste estudo ou depois de
este ter terminado, por favor contacte o me´dico urologista responsa´vel:
Dr. Contacto
Nome do paciente
Assinatura do paciente Data (dd/mm/yyyy)
Nome do me´dico
Assinatura do me´dico Data (dd/mm/yyyy)
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